https://trial.medpath.com/news/pulmatrix-and-eos-senolytix-announce-19-million-merger-to-advance-anti-aging-mitochondrial-therapies 2026-03-26T21:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/oig-approves-medicare-cost-sharing-subsidies-for-heart-failure-device-clinical-trial 2026-03-26T17:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/eurofins-viracor-launches-rapid-car-t-cell-monitoring-assay-for-obe-cel-therapy 2026-03-26T17:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-biopharma-appoints-principal-investigator-for-phase-2-multiple-sclerosis-trial-of-lucid-ms 2026-03-26T17:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/made-scientific-partners-with-njit-to-launch-graduate-cell-and-gene-therapy-bioprocessing-program 2026-03-26T17:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/kodiak-sciences-zenkuda-achieves-primary-endpoint-in-phase-3-diabetic-retinopathy-trial 2026-03-26T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharm-reports-strong-2025-results-with-26-2-growth-in-innovative-drug-sales 2026-03-26T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/kamada-secures-fda-approval-for-san-antonio-plasma-collection-center-expanding-specialty-plasma-production-capacity 2026-03-26T17:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/kodiak-sciences-zenkuda-achieves-62-5-response-rate-in-phase-3-glow2-diabetic-retinopathy-trial 2026-03-26T17:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/meiragtx-receives-fda-breakthrough-therapy-designation-for-gene-therapy-treating-radiation-induced-dry-mouth 2026-03-26T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/mytomorrows-partners-with-spanish-academic-hospital-to-deploy-ai-powered-clinical-trial-matching-system 2026-03-26T17:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/edesa-biotech-prepares-phase-2-vitiligo-trial-for-mid-2026-launch-following-promising-ards-results 2026-03-26T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/neion-bio-secures-23m-series-a-to-scale-egg-based-biologics-manufacturing-platform 2026-03-26T13:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioptimus-launches-stela-world-s-largest-spatial-biology-atlas-to-power-ai-driven-precision-medicine 2026-03-26T13:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/invivoscribe-achieves-ivdr-class-c-certification-for-b-cell-lymphoma-diagnostic-assay-in-europe 2026-03-26T13:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/vagus-nerve-stimulation-shows-promise-for-ptsd-treatment-in-clinical-trials 2026-03-26T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-initiates-phase-1-study-of-tnx-1900-intranasal-oxytocin-for-migraine-treatment 2026-03-26T13:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/norgine-receives-swiss-approval-for-pedmarqsi-first-treatment-to-prevent-cisplatin-induced-hearing-loss-in-children 2026-03-26T13:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/innate-pharma-advances-oncology-pipeline-with-phase-3-trial-plans-and-promising-adc-data 2026-03-26T09:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/imperative-care-launches-clear-it-study-to-establish-clinical-standards-for-peripheral-thromboembolism-treatment 2026-03-26T09:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-and-novartis-mount-legal-challenge-against-illinois-340b-drug-discount-law 2026-03-26T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharmaceuticals-launches-cenobamate-in-china-marking-major-milestone-for-epilepsy-treatment 2026-03-26T09:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/hmh-holding-completes-210-4-million-ipo-pricing-for-drilling-equipment-technology 2026-03-26T05:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/purple-biotech-partners-with-converge-bio-to-accelerate-ai-driven-tri-specific-antibody-development 2026-03-26T05:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/brightgene-s-oral-glp-1-gip-dual-agonist-bgm0504-shows-promising-weight-loss-results-in-phase-1-trials 2026-03-26T05:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/elmed-life-sciences-secures-2-7m-series-a-to-expand-microbiome-based-healthcare-solutions 2026-03-26T05:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/helioliver-blood-test-shows-superior-sensitivity-over-ultrasound-for-early-hepatocellular-carcinoma-detection-in-landmark-climb-study 2026-03-26T03:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/hrt-patches-show-equal-efficacy-to-injections-for-locally-advanced-prostate-cancer-treatment 2026-03-26T01:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/flumatinib-therapeutic-drug-monitoring-reveals-key-exposure-thresholds-for-molecular-response-in-chinese-cml-cp-patients 2026-03-26T01:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/nugen-medical-devices-advances-needle-free-drug-delivery-with-dual-patent-filings-for-enhanced-injection-technology 2026-03-26T01:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/methylphenidate-may-reduce-psychosis-risk-in-children-with-adhd-large-finnish-study-shows 2026-03-26T01:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-oral-drug-delivery-technology-enables-depression-treatment-through-fat-absorption-pathways 2026-03-25T21:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/blood-pressure-drug-telmisartan-shows-promise-in-enhancing-cancer-treatment-effectiveness 2026-03-25T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/fish-oil-supplements-show-no-cognitive-benefit-in-alzheimer-s-prevention-usc-study-finds 2026-03-25T21:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/beyondspring-s-plinabulin-shows-promise-in-overcoming-immunotherapy-resistance-in-nsclc 2026-03-25T17:19:55+00:00 hourly 0.9 https://trial.medpath.com/news/clarity-pharmaceuticals-secures-large-scale-copper-64-manufacturing-agreement-with-theragenics-for-prostate-cancer-diagnostic 2026-03-25T17:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/tropic-biosciences-raises-105-million-series-c-to-scale-gene-edited-tropical-crop-production 2026-03-25T17:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/scitech-s-st-001-nanofenretinide-shows-early-clinical-benefit-in-cutaneous-t-cell-lymphoma-phase-1a-trial 2026-03-25T17:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/axplora-invests-60-million-in-hpapi-manufacturing-expansion-to-meet-growing-adc-demand 2026-03-25T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-apotex-s-clobivis-for-post-cataract-surgery-inflammation-treatment 2026-03-25T17:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/sirolimus-eluting-balloons-show-promise-as-alternative-to-permanent-stents-in-heart-attack-treatment 2026-03-25T17:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/lineage-cell-therapeutics-launches-cor1-cell-therapy-program-to-address-global-corneal-transplant-shortage 2026-03-25T13:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-court-clears-path-for-sawai-s-amitiza-generic-rejecting-viatris-patent-extension-strategy 2026-03-25T13:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/cvc-capital-proposes-eur10-9-billion-takeover-of-italian-pharma-recordati 2026-03-25T13:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/verigraft-initiates-pivotal-phase-ii-iii-trial-for-first-potential-curative-cvi-treatment 2026-03-25T13:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-receives-fda-approval-for-expanded-omniasecure-defibrillation-lead-indication 2026-03-25T13:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/mitsui-chemicals-establishes-drug-discovery-lab-in-kentucky-advancing-next-generation-pharmaceutical-materials 2026-03-25T09:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/veeva-systems-acquires-ai-powered-brand-engagement-platform-ostro-for-100-million 2026-03-25T09:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/hope-medicine-initiates-phase-iii-trial-for-first-in-class-non-hormonal-endometriosis-treatment 2026-03-25T05:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/absci-s-ai-designed-hair-loss-treatment-abs-201-shows-promising-safety-data-in-phase-1-2a-trial 2026-03-25T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/new-cerebrospinal-fluid-biomarker-achieves-94-97-accuracy-in-diagnosing-parkinson-s-disease-and-lewy-body-dementia 2026-03-25T01:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/biolojic-design-s-ai-designed-multibody-tev-325-achieves-preclinical-milestone-for-autoimmune-disease-treatment 2026-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/20-20-biolabs-partners-with-rokit-healthcare-to-integrate-ckd-prediction-technology-into-longevity-testing-platform 2026-03-24T21:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-researchers-develop-breakthrough-nanoparticle-system-for-scalable-exosome-therapeutic-production 2026-03-24T21:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/recce-pharmaceuticals-advances-phase-3-diabetic-foot-infection-trial-following-clean-indonesian-regulatory-inspection 2026-03-24T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/catalyst-pharmaceuticals-settles-firdapse-patent-litigation-with-hetero-labs-securing-market-exclusivity-until-2035 2026-03-24T21:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-advances-dll3-targeting-t-cell-engager-obrixtamig-directly-to-phase-3-first-line-small-cell-lung-cancer-trial 2026-03-24T21:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/myosin-therapeutics-receives-2-million-florida-grant-for-first-in-human-glioblastoma-trial 2026-03-24T21:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/remegen-s-disitamab-vedotin-receives-fourth-nmpa-approval-for-her2-low-breast-cancer-in-china 2026-03-24T21:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/cytiva-partners-with-san-raffaele-institute-to-advance-hematopoietic-stem-cell-gene-therapies 2026-03-24T21:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/italian-drug-approval-reform-shows-mixed-results-on-negotiation-timelines 2026-03-24T21:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letter-to-immunitybio-over-misleading-cancer-drug-claims-by-patrick-soon-shiong 2026-03-24T21:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/28bio-s-cns-3d-brain-organoids-demonstrate-superior-seizure-prediction-accuracy-over-animal-models 2026-03-24T17:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/achieve-life-sciences-partners-with-adare-pharma-for-cytisinicline-manufacturing-ahead-of-fda-decision 2026-03-24T17:13:45+00:00 hourly 0.9 https://trial.medpath.com/news/doctronic-secures-40m-series-b-as-first-ai-system-legally-authorized-to-renew-prescriptions-in-the-u-s 2026-03-24T17:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/apnimed-secures-150m-from-shionogi-joint-venture-sale-advances-first-in-class-osa-drug-toward-fda-submission 2026-03-24T17:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/major-study-finds-no-link-between-covid-19-vaccines-and-sudden-cardiac-death-in-healthy-young-adults 2026-03-24T17:11:18+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-world-s-first-clinical-trial-integrating-ayurveda-with-tuberculosis-treatment 2026-03-24T17:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-cancer-drug-doxorubicin-shows-promise-against-drug-resistant-herpes-infections 2026-03-24T17:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-keytruda-as-first-perioperative-immunotherapy-for-head-and-neck-cancer-in-20-years 2026-03-24T17:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/scotland-launches-first-uk-newborn-screening-program-for-spinal-muscular-atrophy 2026-03-24T17:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/epifrontier-therapeutics-secures-32m-amed-grant-to-advance-first-in-class-g9a-inhibitor-for-beta-globin-disorders 2026-03-24T17:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/ra-capital-raises-75m-through-third-spac-targeting-china-based-biotech-companies 2026-03-24T17:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-secures-new-us-patent-for-intratumoral-cancer-technology 2026-03-24T17:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/continuity-biosciences-partners-with-breakthrough-t1d-to-advance-novel-cell-therapy-platform-for-type-1-diabetes 2026-03-24T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-expands-pain-portfolio-with-fda-cleared-viaverte-basivertebral-nerve-ablation-system 2026-03-24T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/mushrooms-inc-achieves-proof-of-concept-for-mycelium-based-infection-detection-technology 2026-03-24T13:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/callio-therapeutics-initiates-first-in-human-trial-of-dual-payload-adc-clio-8221-for-her2-positive-solid-tumors 2026-03-24T13:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/dualitybio-achieves-phase-3-success-with-lead-adc-candidate-advances-global-pipeline-across-multiple-cancer-types 2026-03-24T13:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/mana-bio-strengthens-leadership-team-and-prepares-to-present-ai-driven-lnp-data-at-asgct-2026 2026-03-24T13:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/immutrin-secures-87-million-series-a-to-advance-novel-antibody-therapy-for-attr-amyloidosis 2026-03-24T13:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/iaso-bio-receives-japan-pmda-approval-for-phase-iii-car-t-trial-in-earlier-line-multiple-myeloma 2026-03-24T13:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/prestige-biopharma-s-hd204-biosimilar-meets-primary-endpoint-in-phase-3-nsclc-trial 2026-03-24T13:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/quotient-therapeutics-partners-with-merck-in-2-2-billion-ibd-drug-discovery-deal-using-somatic-genomics-platform 2026-03-24T13:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/cortexa-achieves-major-commercial-milestone-with-mdma-supply-in-australia-s-regulated-psychedelic-market 2026-03-24T09:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-challenges-takeda-s-ibd-drug-patents-in-uk-biosimilar-dispute 2026-03-24T09:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-biotech-achieves-breakthrough-in-first-line-nsclc-treatment-with-world-s-first-successful-adc-immunotherapy-combination 2026-03-24T09:05:50+00:00 hourly 0.9 https://trial.medpath.com/news/microbot-medical-launches-full-commercial-release-of-liberty-robotic-system-following-successful-limited-market-adoption 2026-03-24T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/pancreatic-cancer-pipeline-reaches-new-milestone-with-200-therapies-from-170-companies-advancing-novel-treatment-approaches 2026-03-24T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/sol-gel-secures-patent-extension-for-patidegib-until-2044-raises-33-1m-to-advance-gorlin-syndrome-trial 2026-03-24T01:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/surrozen-advances-wnt-based-retinal-therapeutics-pipeline-plans-ind-filing-for-szn-8141-in-second-half-of-2026 2026-03-24T01:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-s-microbiome-therapy-shows-62-response-rate-in-severe-graft-versus-host-disease 2026-03-24T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/avalyn-initiates-phase-2-trial-of-inhaled-nintedanib-for-idiopathic-pulmonary-fibrosis 2026-03-24T01:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/celosia-therapeutics-initiates-first-in-human-trial-of-ctx1000-gene-therapy-for-als 2026-03-24T01:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/cencora-expands-retina-care-network-with-1-1-billion-eyesouth-partners-acquisition 2026-03-24T01:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-s-enhanced-epicapture-test-achieves-85-accuracy-in-prostate-cancer-risk-prediction 2026-03-23T21:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-approves-pharmamar-s-zepzelca-combination-as-first-line-maintenance-therapy-for-advanced-small-cell-lung-cancer 2026-03-23T21:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/abpi-proposes-nhs-data-integration-to-revitalize-uk-s-declining-clinical-trial-sector 2026-03-23T21:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-biopharma-s-unbuzzd-supplement-shows-significant-alcohol-metabolism-acceleration-in-peer-reviewed-clinical-trial 2026-03-23T17:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-lomb-s-elios-system-achieves-primary-endpoints-in-24-month-u-s-glaucoma-trial 2026-03-23T17:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/sintx-technologies-achieves-first-human-implant-of-fda-cleared-silicon-nitride-foot-and-ankle-device 2026-03-23T17:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/kraig-biocraft-laboratories-scales-spider-silk-production-with-new-facility-and-enhanced-r-d-capacity 2026-03-23T17:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/roche-opens-institute-of-human-biology-in-basel-with-chf-1-4-billion-investment-to-revolutionize-drug-discovery 2026-03-23T17:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-secures-first-ever-gad-treatment-approval-in-japan-with-effexor 2026-03-23T17:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/german-court-grants-sales-ban-for-generic-fampridine-products-following-patent-victory-for-merz 2026-03-23T17:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/bio-thera-solutions-expands-partnership-with-intas-for-golimumab-biosimilar-bat2506-in-india 2026-03-23T17:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-zilganersen-for-alexander-disease-setting-stage-for-first-treatment 2026-03-23T17:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/godavari-biorefineries-secures-japanese-patent-for-novel-v-atpase-inhibitor-antiviral-compounds 2026-03-23T17:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/apollo-acquires-37-stake-in-syntegon-as-pharmaceutical-packaging-giant-eyes-north-american-expansion 2026-03-23T17:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/stealth-biotherapeutics-secures-mrc-grant-to-advance-sbt-589-for-leigh-syndrome-treatment 2026-03-23T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-completes-2-5-billion-acquisition-of-radicava-for-als-treatment-expanding-rare-disease-portfolio 2026-03-23T17:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/enlivex-receives-fda-ind-clearance-for-phase-2b-trial-of-allocetra-in-age-related-knee-osteoarthritis 2026-03-23T17:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/inmed-s-inm-901-shows-promise-in-human-brain-organoid-models-for-alzheimer-s-disease-treatment 2026-03-23T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/glyconex-partners-with-nippon-kayaku-to-develop-tumor-activated-adc-gnx201-for-solid-tumors 2026-03-23T17:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/ondine-s-steriwave-phase-3-trial-reaches-93-enrollment-milestone-in-landmark-surgical-site-infection-prevention-study 2026-03-23T17:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/biocytogen-partners-with-moonlight-bio-to-develop-advanced-cell-therapies-for-difficult-to-treat-cancers 2026-03-23T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-receives-world-first-approval-for-lunsumio-polivy-combination-in-relapsed-large-b-cell-lymphoma 2026-03-23T13:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/karmanos-cancer-institute-becomes-first-independent-cancer-center-to-offer-hemophilia-b-gene-therapy 2026-03-23T13:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/biolinerx-advances-glix1-glioblastoma-trial-as-company-reports-2025-financial-results 2026-03-23T13:21:33+00:00 hourly 0.9 https://trial.medpath.com/news/endocyclic-therapeutics-receives-fda-ind-clearance-for-first-in-class-non-hormonal-endometriosis-treatment-endo-205 2026-03-23T13:18:30+00:00 hourly 0.9 https://trial.medpath.com/news/laigo-bio-secures-eur17m-in-oversubscribed-seed-round-to-advance-novel-protein-degradation-platform 2026-03-23T13:18:28+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-completes-21-billion-exact-sciences-acquisition-while-novartis-invests-2-billion-in-next-generation-pi3ka-inhibitors 2026-03-23T13:17:42+00:00 hourly 0.9 https://trial.medpath.com/news/just-evotec-biologics-secures-10m-barda-contract-to-optimize-filovirus-antibody-manufacturing 2026-03-23T13:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/brain-biotech-secures-european-patent-for-novel-crispr-bmc-genome-editing-technology 2026-03-23T13:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-and-valneva-s-lyme-disease-vaccine-shows-73-efficacy-in-phase-3-trial 2026-03-23T13:16:51+00:00 hourly 0.9 https://trial.medpath.com/news/fecal-microbiota-transplantation-shows-promise-for-severe-c-difficile-infections-despite-regulatory-challenges 2026-03-23T13:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-orphan-drug-status-to-uab-s-maresin-1-therapy-for-spinal-cord-injuries 2026-03-23T13:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-valneva-lyme-disease-vaccine-shows-73-efficacy-but-faces-regulatory-hurdle-after-missing-statistical-endpoint 2026-03-23T13:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/indian-courts-strengthen-patent-opposition-framework-in-high-profile-cancer-immunotherapy-and-drug-delivery-cases 2026-03-23T09:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/contezolid-shows-superior-safety-profile-to-linezolid-in-real-world-treatment-of-drug-resistant-infections 2026-03-23T09:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/monash-university-and-clinchoice-form-strategic-partnership-to-accelerate-early-phase-clinical-trials 2026-03-23T09:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/hypersomnia-pipeline-advances-with-novel-therapies-from-avadel-zevra-and-alkermes 2026-03-23T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/cleo-diagnostics-expands-ovarian-cancer-test-biomarker-panel-to-eight-markers-ahead-of-fda-submission 2026-03-23T05:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-biologics-initiates-phase-3-trial-for-novel-gout-drug-tigulixostat-in-china 2026-03-23T05:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-s-tslp-targeting-antibody-hbm9378-shows-favorable-safety-profile-in-phase-i-trial 2026-03-23T05:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/digital-pcr-outperforms-standard-rt-qpcr-in-detecting-residual-bcr-abl1-in-cml-patients-enabling-better-tki-discontinuation-decisions 2026-03-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pepsico-analyst-targets-fluctuate-as-company-pursues-price-cuts-and-health-focused-product-pipeline-for-2026-turnaround 2026-03-22T21:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-expert-panel-mandates-protocol-revisions-for-glimepiride-linagliptin-combination-phase-iii-trial 2026-03-22T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/hepatitis-c-drug-bemnifosbuvir-shows-promise-against-hepatitis-e-virus-in-preclinical-studies 2026-03-22T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/vesicor-therapeutics-appoints-michael-tolentino-as-ceo-to-lead-p53-based-cancer-therapy-development 2026-03-22T17:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-comirnaty-vaccine-transitions-to-endemic-phase-with-sustained-european-market-presence 2026-03-22T13:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/siemens-healthineers-partners-with-imaginostics-to-advance-quantitative-mri-technology-for-magnetom-systems 2026-03-22T13:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/clariant-establishes-first-us-manufacturing-site-for-pharmaceutical-grade-peg-excipients-in-texas 2026-03-22T01:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/tg-therapeutics-secures-500-million-credit-facility-to-fuel-briumvi-growth-and-pipeline-development 2026-03-21T21:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/spyre-therapeutics-completes-phase-1-safety-study-of-spy001-001-advancing-early-stage-pipeline 2026-03-21T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/akums-launches-world-s-first-lasmiditan-dispersible-tablets-for-acute-migraine-treatment 2026-03-21T21:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/zegfrovy-achieves-primary-endpoint-in-phase-3-trial-for-first-line-egfr-exon-20-insertion-nsclc 2026-03-21T17:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-mandates-seizure-risk-warnings-for-parkinson-s-drugs-containing-carbidopa-and-levodopa 2026-03-21T13:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/curi-bio-launches-curiversetm-platform-to-scale-3d-human-tissue-models-for-industrial-drug-discovery 2026-03-21T01:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-varian-truebeam-systems-for-low-dose-radiation-therapy-in-osteoarthritis 2026-03-21T01:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-to-present-long-term-povorcitinib-data-for-hidradenitis-suppurativa-at-aad-2026 2026-03-21T01:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-completes-8-9-billion-clario-acquisition-to-strengthen-clinical-trial-capabilities 2026-03-21T01:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/large-clinical-trial-shows-behavioral-hydration-program-fails-to-reduce-kidney-stone-recurrence-despite-smart-bottle-technology 2026-03-21T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/smart-hydrogel-wound-dressing-delivers-antibiotics-on-demand-to-combat-resistance 2026-03-20T19:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-presents-real-world-evidence-for-dermatology-portfolio-at-aad-2026 2026-03-20T17:14:08+00:00 hourly 0.9 https://trial.medpath.com/news/lab-grown-oesophagus-successfully-restores-swallowing-function-in-pigs-human-trials-planned-within-five-years 2026-03-20T17:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/biodesix-publishes-largest-lung-nodule-biomarker-validation-study-supporting-earlier-cancer-detection 2026-03-20T17:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/arch-biopartners-advances-lsalt-peptide-phase-ii-trial-for-cardiac-surgery-associated-acute-kidney-injury 2026-03-20T17:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/mixed-results-from-cardiac-resynchronization-trials-challenge-left-bundle-branch-pacing-as-biv-alternative 2026-03-20T15:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-partners-with-emfret-analytics-to-advance-novel-gpvi-inhibitor-ema601-for-stroke-treatment 2026-03-20T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-acquires-next-generation-pi3ka-inhibitor-snv4818-in-3-billion-deal-to-strengthen-breast-cancer-pipeline 2026-03-20T10:45:28+00:00 hourly 0.9 https://trial.medpath.com/news/bio-sourcing-and-tiny-cargo-partner-to-develop-first-oral-monoclonal-antibody-platform-using-goat-milk-exosomes 2026-03-20T05:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/lunai-bioworks-launches-national-chemical-defense-consortium-with-ai-driven-3-year-antidote-development-model 2026-03-20T05:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/verily-secures-300-million-investment-and-gains-independence-from-alphabet-to-advance-ai-driven-precision-health-platform 2026-03-20T05:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/mayo-clinic-pilot-study-demonstrates-safe-home-based-chemotherapy-delivery 2026-03-20T05:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/adalta-completes-global-patent-protection-for-anti-fibrotic-drug-ad-214-with-canadian-approval 2026-03-20T05:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/nice-ordered-to-reconsider-alzheimer-s-drugs-after-successful-appeals-by-eli-lilly-and-eisai 2026-03-20T05:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/6th-mrna-based-therapeutics-summit-returns-to-boston-with-focus-on-ai-driven-design-in-vivo-cell-engineering-and-global-regulatory-harmonization 2026-03-20T03:53:14+00:00 hourly 0.9 https://trial.medpath.com/news/curis-reports-promising-mrd-conversion-data-for-emavusertib-in-aml-combination-therapy 2026-03-20T01:58:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-blood-test-for-colorectal-cancer-screening-as-american-cancer-society-updates-guidelines 2026-03-19T21:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/collegium-pharmaceutical-acquires-azstarys-for-650-million-to-strengthen-adhd-portfolio 2026-03-19T21:14:32+00:00 hourly 0.9 https://trial.medpath.com/news/ac-immune-achieves-first-in-vivo-imaging-of-tdp-43-brain-pathology-with-novel-pet-tracer-aci-19626 2026-03-19T21:12:28+00:00 hourly 0.9 https://trial.medpath.com/news/context-therapeutics-advances-t-cell-engager-pipeline-with-three-bispecific-antibodies-in-clinical-development 2026-03-19T21:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/triana-biomedicines-tri-611-receives-fda-fast-track-designation-for-alk-nsclc-treatment 2026-03-19T21:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-hookworm-vaccine-demonstrates-significant-protection-in-phase-2-human-trial 2026-03-19T21:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/glaukos-launches-first-fda-approved-epithelium-on-corneal-cross-linking-treatment-for-keratoconus-in-us 2026-03-19T21:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-therapeutics-seeks-traditional-approval-for-duchenne-muscular-dystrophy-therapies-following-fda-feedback 2026-03-19T17:14:35+00:00 hourly 0.9 https://trial.medpath.com/news/convergent-therapeutics-to-present-phase-2-data-for-conv01-a-in-lu-psma-pretreated-metastatic-prostate-cancer-at-asco-2026 2026-03-19T17:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/embecta-acquires-owen-mumford-for-ps150-million-to-expand-drug-delivery-platform-capabilities 2026-03-19T17:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/altesa-biosciences-vapendavir-shows-first-ever-activity-against-rhinovirus-c-in-breakthrough-research 2026-03-19T17:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-shows-early-promise-in-progressive-multiple-sclerosis-first-patients-treated-in-pioneering-trials 2026-03-19T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-remix-therapeutics-rem-422-for-adenoid-cystic-carcinoma-treatment 2026-03-19T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/annovis-bio-partners-with-neurorpm-to-deploy-ai-powered-digital-biomarker-technology-in-parkinson-s-disease-clinical-trial 2026-03-19T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-talzenna-shows-significant-benefit-in-hormone-sensitive-prostate-cancer-trial 2026-03-19T17:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/pharmamar-partners-with-globant-to-deploy-ai-powered-drug-discovery-platform-achieving-15x-faster-cancer-research-insights 2026-03-19T17:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/lytix-biopharma-reports-promising-phase-ii-data-for-ruxotemitide-in-advanced-melanoma-and-triple-negative-breast-cancer 2026-03-19T17:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-digital-health-leader-signals-forthcoming-updates-to-artificial-intelligence-policy 2026-03-19T17:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/providence-medical-technology-launches-superiority-trial-for-corus-lx-lumbar-fusion-system 2026-03-19T17:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/cytosorbents-launches-hotswaptm-technology-and-reports-positive-clinical-data-for-blood-purification-therapy 2026-03-19T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/livanova-s-aura6000-system-receives-fda-approval-for-obstructive-sleep-apnea-treatment 2026-03-19T17:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/chemomab-secures-fda-alignment-for-phase-3-trial-of-nebokitug-in-primary-sclerosing-cholangitis 2026-03-19T14:45:48+00:00 hourly 0.9 https://trial.medpath.com/news/python-derived-metabolite-shows-promise-as-novel-weight-loss-drug-with-reduced-side-effects 2026-03-19T14:45:36+00:00 hourly 0.9 https://trial.medpath.com/news/sk-pharmteco-commits-100-million-to-strengthen-viral-vector-manufacturing-capabilities 2026-03-19T14:45:19+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-manufacturing-solutions-expands-dabhasa-facility-to-scale-peptide-and-adc-manufacturing-capabilities 2026-03-19T14:44:38+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-and-bristol-myers-squibb-advance-novel-molecular-glue-degrader-bms-986506-into-phase-1-trial-for-kidney-cancer 2026-03-19T14:44:12+00:00 hourly 0.9 https://trial.medpath.com/news/eight-week-probiotic-trial-shows-promise-for-functional-gastrointestinal-disorders-in-placebo-controlled-study 2026-03-19T14:44:05+00:00 hourly 0.9 https://trial.medpath.com/news/belief-biomed-s-gene-therapy-bbm-h901-receives-approval-in-macao-for-hemophilia-b-treatment 2026-03-19T14:44:02+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-files-regulatory-application-for-revolutionary-port-delivery-platform-in-japan 2026-03-19T14:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/aspen-neuroscience-s-personalized-parkinson-s-cell-therapy-shows-promise-in-phase-ii-trial-advances-to-pivotal-study 2026-03-19T14:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-develop-revolutionary-mitochondrial-transplantation-therapy-for-parkinson-s-disease-and-genetic-disorders 2026-03-19T11:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/al-s-pharma-s-ap-101-shows-clinically-meaningful-disease-modification-and-prolonged-survival-in-als-phase-2-trial 2026-03-19T09:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-initiates-phase-2-trial-for-first-oral-substrate-reduction-therapy-in-late-onset-pompe-disease 2026-03-19T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/trisalus-publishes-preclinical-data-showing-enhanced-tumor-delivery-and-immune-activation-with-pedd-delivered-nelitolimod 2026-03-19T05:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-advances-multi-product-growth-strategy-with-quest-partnership-and-fda-milestones 2026-03-19T01:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/argentina-repeals-restrictive-pharmaceutical-patent-guidelines-sparking-industry-debate-over-generic-drug-access 2026-03-19T01:04:34+00:00 hourly 0.9 https://trial.medpath.com/news/first-michigan-patient-successfully-receives-fda-approved-sickle-cell-gene-therapy-lyfgenia 2026-03-19T01:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/louisiana-man-becomes-first-in-southeast-to-receive-gene-therapy-for-sickle-cell-disease 2026-03-19T01:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/aptamer-group-launches-radiopharmaceutical-program-with-enhanced-stability-profile 2026-03-19T01:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/pattern-computer-secures-global-patent-protection-for-ai-discovered-triple-negative-breast-cancer-therapy-pci020302 2026-03-18T21:09:59+00:00 hourly 0.9 https://trial.medpath.com/news/kupando-raises-eur10-million-to-advance-dual-tlr-agonist-kup101-into-phase-1b-clinical-trial 2026-03-18T21:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-biosciences-enters-16-3-billion-glaucoma-market-with-fully-funded-clinical-trial-of-art27-13 2026-03-18T21:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/volitionrx-achieves-breakthrough-in-liquid-biopsy-with-99-pure-cancer-dna-isolation 2026-03-18T21:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/diakonos-oncology-to-present-first-in-class-doc1021-dendritic-cell-therapy-data-at-major-cancer-conferences 2026-03-18T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/superstring-capital-management-invests-6-84-million-in-cns-drug-developer-axsome-therapeutics 2026-03-18T21:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/multi-strain-probiotic-shows-promise-in-reducing-bacterial-vaginosis-recurrence 2026-03-18T21:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/us-appeals-court-revives-false-claims-lawsuit-against-four-pharma-giants-over-340b-drug-pricing-violations 2026-03-18T21:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/mindera-health-and-mountaineer-biosciences-launch-subtilitas-platform-for-precision-dermatology-research 2026-03-18T21:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-tbi-related-memory-loss 2026-03-18T21:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/dod-awards-11m-for-novel-ulcerative-colitis-trial-combining-biologic-with-plant-based-nutraceutical 2026-03-18T21:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/new-england-biolabs-and-touchlight-launch-cell-free-dna-synthesis-kit-to-accelerate-gene-therapy-development 2026-03-18T17:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/crossbow-therapeutics-secures-77-million-series-b-to-advance-tcr-mimetic-cancer-immunotherapies 2026-03-18T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/jenavalve-s-trilogy-system-becomes-first-fda-approved-tavr-device-for-severe-aortic-regurgitation 2026-03-18T17:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/first-validated-biomarker-transforms-hormone-therapy-decisions-in-recurrent-prostate-cancer 2026-03-18T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/atrogi-doses-first-patients-in-phase-1-trial-of-exercise-mimicking-drug-atr-258 2026-03-18T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/triplet-therapy-doubles-survival-in-her2-positive-breast-cancer-patients-with-leptomeningeal-metastasis 2026-03-18T17:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-partners-with-university-at-buffalo-to-develop-novel-sjogren-s-syndrome-biomarkers 2026-03-18T17:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/excalipoint-therapeutics-secures-68-7-million-in-seed-funding-to-advance-next-generation-t-cell-engager-pipeline 2026-03-18T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/merit-medical-launches-resilience-tts-esophageal-stent-for-cancer-related-strictures-and-fistulas 2026-03-18T15:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/eco-innovation-group-acquires-kepler-gtl-s-patent-portfolio-for-sustainable-aviation-fuel-production 2026-03-18T14:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/duke-researchers-develop-nasal-swab-test-for-early-alzheimer-s-detection 2026-03-18T13:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-commits-180m-for-kali-s-novel-trispecific-antibody-in-autoimmune-disease-partnership 2026-03-18T12:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/biotheryx-advances-btx-9341-cdk4-6-degrader-into-dose-expansion-phase-for-hr-her2-breast-cancer 2026-03-18T11:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-first-non-tobacco-flavored-e-cigarettes-with-advanced-age-gating-technology 2026-03-18T09:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-approves-first-enterovirus-a71-vaccine-as-mvc-and-substipharm-target-southeast-asian-expansion 2026-03-18T09:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-sheffield-receives-ps1m-grant-to-develop-smart-gel-drug-delivery-system-for-glioblastoma 2026-03-18T05:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/silexion-therapeutics-receives-israeli-regulatory-approval-for-phase-2-3-trial-of-kras-targeting-rnai-therapy-sil204 2026-03-18T01:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/akamis-bio-s-ng-350a-shows-50-response-rate-in-locally-advanced-rectal-cancer-phase-1b-trial 2026-03-18T01:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-ends-flovent-monopoly-after-senate-investigation-reveals-367-million-medicaid-rebate-avoidance 2026-03-18T01:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/zymeworks-advances-novel-ras-targeting-adc-platform-with-clinical-data-from-zw191-at-aacr-2026 2026-03-18T01:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/immunitas-therapeutics-to-present-first-in-human-data-for-novel-anti-cd161-antibody-imt-009-at-aacr-2026 2026-03-18T01:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/blossomhill-therapeutics-unveils-next-generation-pan-kras-inhibitors-with-picomolar-potency-at-aacr-2026 2026-03-18T01:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-orders-patent-office-to-resolve-novartis-breast-cancer-drug-application-after-13-year-delay 2026-03-18T01:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/peijia-medical-s-dcwire-micro-guidewire-receives-first-fda-510-k-clearance-opening-u-s-market-entry 2026-03-18T01:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/verismo-therapeutics-reports-first-clinical-data-for-novel-multi-chain-kir-car-therapies-at-aacr-2026 2026-03-18T01:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/sionna-therapeutics-advances-cftr-modulators-for-cystic-fibrosis-with-strong-analyst-support-and-summer-data-readouts 2026-03-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-and-exact-sciences-present-breakthrough-multi-cancer-early-detection-data-at-aacr-2026 2026-03-17T21:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/r1-therapeutics-launches-with-77-5-million-series-a-to-develop-novel-chronic-kidney-disease-treatment 2026-03-17T21:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/act-capital-management-invests-8-million-in-tg-therapeutics-despite-30-stock-decline 2026-03-17T21:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/first-european-real-world-analysis-validates-immunowell-jcv-test-for-pml-risk-assessment-in-multiple-sclerosis-patients 2026-03-17T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/caribou-biosciences-allogeneic-car-t-therapy-shows-promising-durability-data-in-latest-clinical-update 2026-03-17T21:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-scientists-discover-fructose-metabolism-pathway-drives-glioblastoma-growth-and-immune-suppression 2026-03-17T21:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharmaceutical-receives-nmpa-approval-for-first-in-class-osteoarthritis-drug-trd221-clinical-trial 2026-03-17T21:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/egypt-and-takeda-pharmaceutical-strengthen-research-partnership-to-advance-clinical-trials-and-drug-access 2026-03-17T21:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-follow-up-data-confirm-sustained-survival-benefits-of-pd-1-inhibitors-in-nasopharyngeal-and-esophageal-cancers 2026-03-17T21:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/nice-suspends-resminostat-appraisal-after-company-withdraws-marketing-authorization-application 2026-03-17T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-reports-long-term-hpv-vaccine-efficacy-data-spanning-up-to-18-years 2026-03-17T21:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/uc-berkeley-researchers-develop-machine-learning-methods-to-accelerate-drug-development-using-real-world-evidence 2026-03-17T21:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/cellprothera-advances-protheracytes-stem-cell-therapy-to-phase-iii-for-post-mi-heart-failure 2026-03-17T21:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/asimov-partners-with-score-pharma-to-develop-enhanced-anti-her2-antibody-therapeutics-for-breast-cancer 2026-03-17T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/voro-therapeutics-partners-with-daiichi-sankyo-to-develop-tumor-activated-adcs-using-primebody-platform 2026-03-17T17:13:39+00:00 hourly 0.9 https://trial.medpath.com/news/grifols-chronos-platform-detects-parkinson-s-disease-biomarkers-up-to-12-years-before-clinical-diagnosis 2026-03-17T17:12:19+00:00 hourly 0.9 https://trial.medpath.com/news/spago-nanomedical-s-177lu-sn201-shows-continued-safety-in-phase-i-iia-trial-across-multiple-solid-tumors 2026-03-17T17:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/avance-clinical-appoints-liahna-toy-to-lead-global-early-phase-center-of-excellence 2026-03-17T17:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/vst-bio-secures-45m-series-a-to-advance-first-in-class-stroke-therapeutic-vb-001-into-human-trials 2026-03-17T17:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-bio-partners-with-terumo-to-automate-regulatory-t-cell-manufacturing-for-transplant-therapy 2026-03-17T17:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/osm-car-t-therapy-shows-promise-against-osteosarcoma-in-preclinical-studies 2026-03-17T17:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/alzpath-s-ptau217-antibody-gains-widespread-validation-at-ad-pd-2026-conference 2026-03-17T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/idel-therapeutics-raises-eur9-million-to-advance-direct-cytosolic-drug-delivery-platform-for-cancer-treatment 2026-03-17T17:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/liminatus-pharma-plans-phase-1-trial-of-iba101-cd47-blocking-antibody-for-lung-cancer 2026-03-17T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/innorna-receives-fda-clearance-for-first-in-class-mrna-therapy-in026-targeting-refractory-gout 2026-03-17T17:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/start-partners-with-trialing-to-expand-access-to-oncology-clinical-trials-across-europe 2026-03-17T17:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-aldeyra-s-dry-eye-disease-drug-reproxalap-for-third-time-citing-insufficient-efficacy 2026-03-17T17:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-uncover-how-lecanemab-activates-brain-s-immune-cells-to-clear-alzheimer-s-plaques 2026-03-17T17:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/pixelgen-technologies-partners-with-karolinska-institutet-to-discover-novel-biomarkers-for-cancer-immunotherapy-response 2026-03-17T13:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-review-finds-no-evidence-of-medicinal-cannabis-efficacy-for-major-mental-health-disorders 2026-03-17T13:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/immupharma-secures-ps7-5m-funding-to-advance-kapiglucagon-for-type-1-diabetes-artificial-pancreas-systems 2026-03-17T13:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/crism-therapeutics-secures-fda-orphan-drug-designation-for-brain-cancer-treatment 2026-03-17T13:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/sequential-secures-3-5m-to-develop-ai-powered-platform-for-skin-health-biomarker-discovery 2026-03-17T13:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/outrun-therapeutics-advances-first-in-class-e6ap-inhibitor-for-hpv-positive-head-and-neck-cancer 2026-03-17T13:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/merck-presents-positive-phase-3-data-for-oral-pcsk9-inhibitor-enlicitide-at-acc-26 2026-03-17T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/r1-therapeutics-launches-with-77-5m-to-develop-novel-kidney-disease-treatment 2026-03-17T13:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/soley-therapeutics-develops-first-in-class-ckap2-modulator-stx-6398-for-cancer-treatment 2026-03-17T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/iron-mediated-ferroptosis-impairs-car-t-cell-function-and-antitumor-efficacy-in-multiple-myeloma 2026-03-17T09:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/lightbridge-secures-key-patent-approvals-for-advanced-nuclear-fuel-technology-in-canada-and-europe 2026-03-17T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/jamp-pharma-group-launches-generic-enzalutamide-for-prostate-cancer-treatment-in-canada 2026-03-17T05:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/england-launches-one-off-menb-vaccination-programme-for-students-ahead-of-2026-academic-year 2026-03-17T03:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-engineer-bacteria-to-transform-plastic-waste-into-parkinson-s-drug-l-dopa 2026-03-17T01:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/dual-drug-combinations-show-promise-in-overcoming-multiple-myeloma-resistance 2026-03-17T01:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/pyc-therapeutics-advances-two-rna-based-therapies-for-inherited-blindness-conditions 2026-03-17T01:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-completes-11-billion-bond-sale-to-finance-avidity-biosciences-acquisition 2026-03-17T01:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/ibio-advances-bispecific-antibody-for-pulmonary-hypertension-in-heart-failure-targets-q3-2026-development-candidate 2026-03-17T01:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-s-intranasal-delivery-system-advances-ltr-pharma-s-spontan-phase-ii-trial-for-erectile-dysfunction 2026-03-17T01:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/gnq-insilico-to-go-public-through-500m-spac-deal-advancing-ai-powered-drug-development-platforms 2026-03-17T01:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-announces-us-launch-of-potassium-phosphates-injection-for-hypophosphatemia-treatment 2026-03-17T01:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/datatrak-and-tailrd-heart-form-strategic-partnership-to-advance-ai-driven-cardiovascular-clinical-research 2026-03-17T01:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/metis-techbio-debuts-on-hong-kong-exchange-as-world-s-first-publicly-listed-ai-powered-drug-delivery-company 2026-03-16T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/briohealth-reaches-100-briovad-implants-gains-fda-approval-for-pediatric-heart-failure-trial 2026-03-16T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/bulgold-closes-1-17-million-private-placement-to-advance-slovak-gold-project-development 2026-03-16T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/solve-gne-advances-first-gene-therapy-for-gne-myopathy-toward-phase-i-clinical-trial 2026-03-16T21:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/avicanna-launches-phase-i-clinical-trial-to-determine-optimal-thc-dosing-for-anxiety-treatment 2026-03-16T21:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/sona-nanotech-s-targeted-hyperthermia-therapy-shows-38-tumor-clearance-in-colorectal-cancer-study 2026-03-16T21:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/sartorius-unveils-eveo-platform-to-transform-cell-therapy-manufacturing-with-90-cost-reduction 2026-03-16T21:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/neximmune-advances-nex-ile12-immunotherapy-in-phase-1-trials-with-promising-safety-profile 2026-03-16T21:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-first-formal-guidance-on-form-483-response-requirements-for-drug-manufacturers 2026-03-16T21:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/egret-therapeutics-moves-to-acquire-full-ownership-of-first-in-class-pd-1-agonist-for-stroke-related-brain-swelling 2026-03-16T21:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/prodeon-medical-s-urocross-expander-system-receives-fda-clearance-for-non-permanent-bph-treatment 2026-03-16T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/black-diamond-therapeutics-reports-promising-phase-2-data-for-silevertinib-in-egfr-mutant-cancers 2026-03-16T20:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/blue-light-cystoscopy-shows-superior-detection-and-cost-effectiveness-in-high-risk-bladder-cancer-management 2026-03-16T17:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/amlogenyx-reports-promising-preclinical-data-for-am805-gene-therapy-in-alzheimer-s-disease-treatment 2026-03-16T17:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/avethera-gmbh-acquires-fraunhofer-item-braunschweig-site-to-expand-biopharmaceutical-manufacturing 2026-03-16T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/ternary-therapeutics-secures-ps3-6m-to-advance-ai-driven-molecular-glue-drug-discovery-platform 2026-03-16T17:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-partners-with-veritas-genetics-to-integrate-whole-genome-sequencing-into-health-insurance-plans 2026-03-16T17:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/sentynl-therapeutics-licenses-progerinin-for-hutchinson-gilford-progeria-syndrome-treatment 2026-03-16T17:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/elevara-medicines-initiates-phase-2b-trial-of-novel-cdk4-6-inhibitor-elv001-for-treatment-resistant-rheumatoid-arthritis 2026-03-16T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-reports-positive-phase-1b-results-for-lu-af28996-in-advanced-parkinson-s-disease 2026-03-16T13:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-shows-96-accuracy-in-detecting-glioblastoma-offering-hope-for-earlier-diagnosis 2026-03-16T13:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/scinus-group-secures-eur3-million-to-advance-cell-therapy-manufacturing-platform 2026-03-16T13:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/grit-biotechnologies-receives-fda-ind-clearance-for-gene-edited-til-therapy-gt307 2026-03-16T13:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/organoid-science-receives-world-s-first-ind-approval-for-intestinal-organoid-therapy-in-crohn-s-disease 2026-03-16T13:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/super-vision-technology-s-i-nys-implant-receives-china-approval-as-world-s-first-treatment-for-congenital-nystagmus 2026-03-16T13:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/piramal-pharma-solutions-achieves-major-adc-manufacturing-milestone-with-1500th-batch-delivery 2026-03-16T13:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/novel-protein-carrier-boosts-paclitaxel-solubility-3600-fold-in-targeted-cancer-therapy 2026-03-16T09:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/gen-pharmaceuticals-receives-ethical-approval-for-phase-ii-parkinson-s-disease-trial-of-mitochondrial-targeting-drug-sul-238 2026-03-16T09:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-finerenone-achieves-primary-endpoint-in-phase-iii-find-ckd-trial-for-non-diabetic-chronic-kidney-disease 2026-03-16T09:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/life-sciences-industry-leaders-call-for-systemic-change-to-address-persistent-gender-gap-in-stem 2026-03-16T06:26:14+00:00 hourly 0.9 https://trial.medpath.com/news/cutia-therapeutics-receives-nmpa-approval-for-topical-dutasteride-clinical-trial-in-androgenetic-alopecia 2026-03-16T05:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/tetratherix-launches-precision-medicine-platform-with-30m-partnership-for-nasal-drug-delivery 2026-03-16T05:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/blinklab-advances-autism-diagnostic-device-toward-fda-clearance-with-pivotal-trial-launch 2026-03-16T05:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-therapeutics-raises-2-2-million-to-advance-vista-targeting-cancer-therapy-hmbd-002 2026-03-16T01:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/racura-oncology-receives-approval-for-phase-1-trial-of-rc220-combination-therapy-in-egfr-mutant-lung-cancer 2026-03-16T01:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-mrna-cancer-vaccine-shows-promise-in-canine-trial-sparks-human-treatment-potential 2026-03-15T13:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/firefly-neuroscience-discovers-brain-wave-biomarkers-to-distinguish-adhd-subtypes 2026-03-14T21:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/ono-pharmaceutical-completes-two-key-oncology-studies-as-pipeline-advances 2026-03-14T21:05:21+00:00 hourly 0.9 https://trial.medpath.com/news/fibrogen-refocuses-on-oncology-pipeline-following-china-divestiture-extends-runway-through-2028 2026-03-14T21:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-engineer-bacteria-to-boost-doxorubicin-production-by-180-overcoming-50-year-manufacturing-challenge 2026-03-14T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/uk-patient-becomes-first-to-receive-experimental-antibody-drug-conjugate-for-metastatic-prostate-cancer 2026-03-14T17:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/duke-clinical-trial-shows-promising-results-for-first-line-immunotherapy-in-metastatic-colorectal-cancer 2026-03-14T17:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/korean-biotech-companies-to-showcase-next-generation-cancer-therapies-at-aacr-2026 2026-03-14T13:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/google-s-amie-ai-assistant-demonstrates-doctor-level-diagnostic-performance-in-first-real-world-clinical-trial 2026-03-14T09:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/vimgreen-s-a2a-receptor-antagonist-vg081821-receives-first-global-ind-approval-for-nash-treatment 2026-03-14T09:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/hawkeye-bio-secures-patent-for-graphene-biosensor-platform-targeting-early-lung-cancer-detection 2026-03-14T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/combat-medical-advances-hivec-heat-trial-for-bcg-unresponsive-bladder-cancer-with-ps2-6-million-series-a-funding 2026-03-14T06:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/duke-engineers-develop-sonopin-technology-to-enhance-delivery-of-large-cancer-therapeutics 2026-03-14T01:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-committee-recommends-including-subclade-k-variant-in-fall-2024-flu-vaccines 2026-03-14T01:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/hydracs-protein-like-polymers-open-new-frontier-in-targeted-protein-degradation-for-undruggable-cancer-targets 2026-03-13T21:11:57+00:00 hourly 0.9 https://trial.medpath.com/news/eliquis-demonstrates-superior-safety-profile-over-xarelto-in-direct-comparison-trial-for-venous-thrombosis 2026-03-13T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/einstein-scientists-develop-novel-car-t-manufacturing-method-to-extend-therapeutic-durability 2026-03-13T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-erda-idrs-shows-89-complete-response-rate-in-first-in-human-bladder-cancer-study 2026-03-13T21:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-ag-secures-eur650m-biosimilar-partnership-with-athos-kg-in-landmark-deal 2026-03-13T21:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/tevogen-bio-s-ai-platform-achieves-breakthrough-in-drug-target-prediction-with-92-accuracy 2026-03-13T21:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-cosentyx-for-pediatric-hidradenitis-suppurativa-marking-first-il-17a-inhibitor-for-adolescents 2026-03-13T21:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/lonza-completes-strategic-transformation-with-3-billion-divestment-of-capsules-health-ingredients-business 2026-03-13T21:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/unixell-biotech-receives-fda-ind-clearance-for-first-ipsc-derived-allogeneic-cell-therapy-for-focal-epilepsy 2026-03-13T17:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/barinthus-bio-completes-phase-1-celiac-disease-trial-as-company-prepares-for-strategic-merger 2026-03-13T17:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-achieves-manufacturing-breakthrough-for-nk-cell-therapy-platform-with-scalable-production-process 2026-03-13T17:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/insulet-recalls-omnipod-5-insulin-pumps-after-18-serious-adverse-events-due-to-internal-tubing-defect 2026-03-13T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-desidustat-tablets-for-renal-anemia-addressing-critical-treatment-gap-in-ckd-patients 2026-03-13T17:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/aditxt-acquires-ignite-proteomics-for-36-million-to-advance-precision-oncology-platform 2026-03-13T17:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/fridge-free-tetanus-and-diphtheria-vaccine-shows-promise-in-phase-1-trials-advances-to-next-clinical-stage 2026-03-13T17:07:47+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-world-s-first-commercial-brain-computer-interface-for-spinal-cord-injury-treatment 2026-03-13T17:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/who-releases-target-product-profiles-to-guide-development-of-antibiotics-against-priority-pathogens 2026-03-13T17:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/century-health-partners-with-dallas-renal-group-to-advance-ai-driven-research-in-rare-kidney-diseases 2026-03-13T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/topical-cream-activates-skin-s-immune-system-to-suppress-cutaneous-squamous-cell-carcinoma-growth 2026-03-13T17:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/major-insurers-expand-coverage-for-peripheral-nerve-stimulation-systems-improving-access-for-chronic-pain-patients 2026-03-13T09:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/penn-spinout-linnaeus-therapeutics-secures-22-million-federal-grant-to-advance-anti-aging-drug-lns8801 2026-03-13T09:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/creative-biolabs-advances-mrna-therapeutics-with-novel-lnp-conjugation-and-lpp-delivery-platforms 2026-03-13T09:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/colombia-partners-with-3pbiovian-to-develop-first-domestic-biosimilar-cancer-drug 2026-03-13T09:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/elicio-therapeutics-reports-encouraging-phase-2-amplify-7p-trial-progress-with-fewer-disease-events-than-projected 2026-03-13T05:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/eve-health-group-secures-904000-to-advance-reformulated-pharmaceutical-pipeline 2026-03-13T05:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-halts-phase-iii-lung-cancer-trial-after-futility-analysis-shares-plunge-88 2026-03-13T05:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/immunobrain-reports-phase-1b-results-for-novel-pd-l1-checkpoint-inhibitor-in-alzheimer-s-disease 2026-03-13T02:41:01+00:00 hourly 0.9 https://trial.medpath.com/news/waiv-raises-33m-to-scale-ai-powered-cancer-precision-testing-platform-globally 2026-03-13T02:39:39+00:00 hourly 0.9 https://trial.medpath.com/news/mbx-biosciences-appoints-karen-basbaum-as-chief-business-officer-to-drive-strategic-partnerships 2026-03-12T21:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/foundation-medicine-expands-beyond-oncology-with-whole-genome-sequencing-test-for-cardiometabolic-and-neurologic-diseases 2026-03-12T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/costco-partners-with-sesame-and-ivi-rma-to-transform-fertility-care-access-with-80-medication-savings 2026-03-12T21:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-and-sanofi-settle-decade-long-patent-dispute-over-pcsk9-cholesterol-drugs 2026-03-12T21:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/vienna-s-valanx-biotech-secures-eur3-million-to-advance-precision-adc-platform-for-triple-negative-breast-cancer 2026-03-12T21:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/biocurie-secures-9-3m-arpa-h-award-to-develop-ai-powered-gene-therapy-manufacturing-platform 2026-03-12T21:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/psiquantum-partners-with-national-cancer-center-japan-to-advance-quantum-computing-in-drug-discovery 2026-03-12T21:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/structured-exercise-program-reduces-chemo-brain-in-phase-3-trial 2026-03-12T21:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-weight-loss-medications-linked-to-nutrient-deficiencies-and-emerging-health-complications 2026-03-12T18:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/mestag-therapeutics-to-present-novel-ltbr-agonist-mst-0312-data-at-cancer-immunotherapy-symposium 2026-03-12T17:11:46+00:00 hourly 0.9 https://trial.medpath.com/news/rice-university-bioengineer-receives-2-2m-gates-foundation-grant-for-revolutionary-long-acting-cell-factory-implants 2026-03-12T17:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/nsw-opens-96-million-rna-manufacturing-facility-as-university-of-sydney-spinout-secures-tb-vaccine-funding 2026-03-12T17:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/galimedix-achieves-phase-1-milestone-for-oral-gal-101-in-alzheimer-s-disease-development 2026-03-12T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/aplagon-doses-first-patient-in-phase-2a-trial-of-apac-for-chronic-limb-threatening-ischemia 2026-03-12T17:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-names-michelle-werner-as-north-america-president-to-drive-growth-strategy 2026-03-12T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/natera-launches-zenith-genomics-platform-with-methylation-analysis-for-rare-disease-diagnosis 2026-03-12T17:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-gene-therapy-dtx301-demonstrates-significant-ammonia-reduction-in-phase-3-otc-deficiency-trial 2026-03-12T17:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/medically-supervised-ketogenic-diet-extends-survival-by-34-in-metastatic-pancreatic-cancer-patients 2026-03-12T17:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-scientists-develop-light-driven-method-for-late-stage-drug-modification 2026-03-12T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-receives-fda-approval-for-tecnis-puresee-iol-first-extended-depth-of-focus-lens-without-contrast-sensitivity-warning 2026-03-12T17:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/soleno-therapeutics-faces-class-action-lawsuit-over-alleged-clinical-trial-integrity-issues-for-prader-willi-syndrome-drug 2026-03-12T17:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/cbio-receives-european-clearance-for-first-in-human-trial-of-novel-t-cell-therapy-in-cervical-cancer 2026-03-12T13:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-warns-of-dangerous-impurity-in-compounded-tirzepatide-b12-combinations 2026-03-12T13:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-prime-designation-to-tolerogenixx-s-mic-lx-cell-therapy-for-kidney-transplant-tolerance 2026-03-12T13:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-medical-team-achieves-functional-remission-in-30-type-1-diabetes-patients-through-integrative-medicine-approach 2026-03-12T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-reports-promising-early-results-for-int230-6-in-triple-negative-breast-cancer-phase-2-trial 2026-03-12T13:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-partners-with-imperial-and-oxford-to-launch-ps11m-digital-organ-twins-center-for-drug-discovery 2026-03-12T13:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/gesynta-pharma-initiates-phase-ii-trial-of-non-hormonal-endometriosis-treatment-vipoglanstat 2026-03-12T13:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/genscript-opens-first-european-mrna-production-facility-in-netherlands 2026-03-12T09:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/meiji-seika-pharma-launches-phase-i-trial-of-me3241-novel-pd-1-agonist-for-autoimmune-diseases 2026-03-12T09:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/huons-advances-novel-dry-eye-treatment-huc1-394-to-phase-2-clinical-trial 2026-03-12T09:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/preludedx-receives-fda-breakthrough-device-designation-for-aidabreast-multi-omic-test-in-early-stage-breast-cancer 2026-03-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eau-guidelines-upgrade-aquablation-therapy-to-strong-surgical-recommendation-for-bph-treatment 2026-03-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/connected-drug-delivery-devices-market-set-to-reach-12-7-billion-by-2035-driven-by-chronic-disease-rise-and-digital-health-integration 2026-03-12T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/apixaban-shows-superior-safety-profile-over-rivaroxaban-in-major-venous-thromboembolism-trial 2026-03-12T05:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/mesoblast-appoints-dr-teresa-montagut-to-lead-clinical-development-and-medical-affairs-for-cell-therapy-expansion 2026-03-12T05:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/brazil-launches-world-s-first-pediatric-tafenoquine-treatment-for-malaria-in-indigenous-communities 2026-03-12T05:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/pierre-fabre-s-avene-pioneers-ai-enhanced-clinical-studies-for-acne-treatment-in-dermo-cosmetics 2026-03-12T01:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/proton-beam-therapy-trial-shows-promise-for-mesothelioma-patients-aims-to-double-two-year-survival-rates 2026-03-12T01:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-advances-deep-brain-stimulation-trial-for-drug-resistant-motor-epilepsy 2026-03-12T01:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/romiplostim-prevents-chemotherapy-induced-thrombocytopenia-in-phase-3-trial 2026-03-12T01:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/vitestro-secures-70m-series-b-to-advance-autonomous-blood-collection-robot-for-us-market-entry 2026-03-12T01:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-develops-simplified-nanoparticles-for-in-body-car-t-cell-engineering 2026-03-11T21:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/curatis-partners-with-neupharma-for-corticorelin-development-in-japan-s-brain-edema-market 2026-03-11T21:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/viagra-shows-promise-as-first-treatment-for-fatal-childhood-disease-leigh-syndrome 2026-03-11T21:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/uk-health-authorities-launch-joint-initiative-to-support-infectious-disease-trials-in-africa-and-asia 2026-03-11T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-introduces-device-access-restrictions-framework-for-flavored-e-cigarette-regulation 2026-03-11T17:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/biocorrx-secures-u-s-patent-for-biodegradable-naltrexone-implant-technology 2026-03-11T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/dna-origami-vaccine-platform-shows-promise-as-next-generation-alternative-to-mrna-vaccines 2026-03-11T17:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/spinogenix-completes-enrollment-in-phase-2-trial-of-tazbentetol-for-schizophrenia-treatment 2026-03-11T17:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/anacardio-secures-us-patent-for-heart-failure-drug-ac01-extending-protection-until-2042 2026-03-11T17:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharmaceutical-receives-nmpa-approval-for-pan-kras-inhibitor-tqb3205-clinical-trial 2026-03-11T17:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/vima-therapeutics-raises-100m-to-advance-oral-therapy-for-movement-disorders 2026-03-11T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-memed-s-ai-powered-infection-test 2026-03-11T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/arthex-biotech-receives-fda-fast-track-designation-for-atx-01-in-myotonic-dystrophy-type-1 2026-03-11T17:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/verve-medical-initiates-u-s-pilot-trial-for-novel-renal-denervation-therapy-following-promising-tusk-results 2026-03-11T17:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/difgen-pharmaceuticals-secures-fda-approval-for-generic-mesalamine-extended-release-capsules 2026-03-11T17:03:24+00:00 hourly 0.9 https://trial.medpath.com/news/commit-biologics-names-serial-biotech-entrepreneur-as-ceo-to-advance-complement-powered-immunotherapies 2026-03-11T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/nice-reverses-decision-approves-genmab-s-tivdak-for-nhs-use-in-cervical-cancer 2026-03-11T13:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/c2n-diagnostics-expands-alzheimer-s-blood-test-access-across-asia-through-strategic-partnerships 2026-03-11T13:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-two-advanced-neurovascular-catheters-for-stroke-and-complex-brain-procedures 2026-03-11T10:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharmather-advances-microneedle-patch-platform-for-therapeutic-peptides-with-patchprint-manufacturing-system 2026-03-11T09:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/profound-medical-to-present-first-captain-trial-results-comparing-tulsa-procedure-to-robotic-prostatectomy 2026-03-11T09:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/sanara-medtech-s-celleraterx-surgical-powder-shows-3852-cost-savings-per-patient-in-spine-surgery-study 2026-03-11T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/patrys-initiates-manufacturing-and-fda-engagement-for-injectable-delirium-treatment-rls-2201 2026-03-11T05:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/acurastem-receives-target-als-grant-to-develop-syf2-targeted-therapeutics-for-tdp-43-dysfunction 2026-03-11T01:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/heartbeam-partners-with-mount-sinai-to-develop-ai-powered-home-cardiac-monitoring-platform 2026-03-11T01:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/imagenebio-secures-30m-funding-to-advance-ox40-antagonist-img-007-through-phase-2-trials 2026-03-11T01:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/q32-bio-reports-positive-clinical-progress-for-bempikibart-in-alopecia-areata-with-36-week-data-expected-mid-2026 2026-03-11T01:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/red-light-holland-acquires-filament-health-in-strategic-psychedelic-drug-development-merger 2026-03-11T01:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/mindimmune-secures-5-million-addf-investment-to-advance-first-in-class-alzheimer-s-immunotherapy-miti-101 2026-03-11T01:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/ems-acquires-sanofi-s-medley-for-500m-plans-semaglutide-generic-launch-in-brazil 2026-03-11T01:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-cbd-pilot-program-sparks-debate-over-fda-standards-for-cannabinoid-reimbursement 2026-03-11T01:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-study-identifies-statins-and-alpha-blockers-as-potential-life-extending-treatments-for-als-patients 2026-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurothera-labs-acquires-majority-stake-in-cliniquantum-to-advance-quantum-powered-clinical-trials 2026-03-10T21:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-photoswitch-therapy-shows-promise-for-advanced-retinitis-pigmentosa 2026-03-10T21:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/cerevance-reports-positive-phase-2-results-for-novel-parkinson-s-drug-solengepras-targeting-motor-fluctuations-and-sleep-symptoms 2026-03-10T17:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/alligator-bioscience-secures-uspto-patent-for-tetravalent-bispecific-antibody-platform 2026-03-10T17:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/macrogenics-advances-adc-pipeline-with-three-clinical-programs-set-for-2026-data-readouts 2026-03-10T17:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/nkgen-biotech-s-troculeucel-shows-dose-dependent-cognitive-benefits-in-phase-1-alzheimer-s-disease-trials 2026-03-10T17:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/qlaris-bio-appoints-fred-guerard-as-ceo-as-qls-111-glaucoma-drug-enters-phase-3-development 2026-03-10T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/biovaxys-and-adiverna-partner-to-develop-world-s-first-ai-designed-mrna-vaccines-for-companion-animals 2026-03-10T17:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/piston-bio-secures-fda-alignment-for-first-in-class-cancer-related-apathy-treatment-pst-101 2026-03-10T17:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/aptorum-group-and-diamir-biosciences-publish-breakthrough-study-on-blood-based-glioblastoma-detection-using-microrna-biomarkers 2026-03-10T17:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/ck-life-sciences-establishes-sequencio-therapeutics-to-advance-therapeutic-cancer-vaccine-portfolio 2026-03-10T17:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/microbix-advances-manufacturing-modernization-for-kinlytic-urokinase-clot-dissolving-drug 2026-03-10T17:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/spark-biomedical-launches-phase-ii-luna-trial-testing-wearable-neurostimulation-for-heavy-menstrual-bleeding 2026-03-10T17:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/foundation-medicine-expands-combomatch-participation-with-blood-based-biomarker-testing 2026-03-10T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/peptilogics-initiates-pivotal-trial-for-first-in-class-anti-biofilm-drug-plg0206-targeting-prosthetic-joint-infections 2026-03-10T17:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-treatment-for-rare-cerebral-folate-transport-deficiency 2026-03-10T17:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/kcas-bio-lyon-site-achieves-level-a-glp-compliance-renewal-strengthening-ind-enabling-study-support 2026-03-10T17:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/etvax-oral-vaccine-shows-promise-against-deadly-e-coli-infections-in-children 2026-03-10T15:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/idorsia-expands-quviviq-access-to-gulf-states-through-pharmalink-partnership 2026-03-10T13:15:24+00:00 hourly 0.9 https://trial.medpath.com/news/c-further-launches-first-pediatric-cancer-programs-with-40m-budget-partners-with-mink-therapeutics 2026-03-10T13:15:19+00:00 hourly 0.9 https://trial.medpath.com/news/daily-multivitamin-supplementation-slows-biological-aging-by-up-to-5-months-in-randomized-trial 2026-03-10T13:14:46+00:00 hourly 0.9 https://trial.medpath.com/news/korro-bio-advances-rna-editing-platform-with-krro-121-nomination-and-85-million-financing 2026-03-10T13:14:40+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-nanopore-and-lonza-launch-first-gmp-grade-direct-rna-sequencing-solution-for-mrna-quality-control 2026-03-10T13:14:27+00:00 hourly 0.9 https://trial.medpath.com/news/lipum-secures-eur8-million-eu-grant-for-phase-2-rheumatoid-arthritis-trial-of-novel-bssl-targeting-antibody 2026-03-10T13:13:24+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-develop-face-platform-to-overcome-car-t-therapy-resistance-in-leukemia 2026-03-10T13:13:19+00:00 hourly 0.9 https://trial.medpath.com/news/kainova-therapeutics-reports-positive-phase-i-results-for-oral-ep4-receptor-antagonist-dt-9081-in-advanced-solid-tumors 2026-03-10T13:13:15+00:00 hourly 0.9 https://trial.medpath.com/news/nuformix-secures-fda-orphan-drug-designation-for-inhaled-ipf-therapy-nxp002 2026-03-10T13:12:53+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-co-founders-sahin-and-tureci-to-establish-new-mrna-company-by-2026 2026-03-10T13:12:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-eliminates-two-trial-requirement-for-drug-approvals-shifting-to-single-trial-default 2026-03-10T13:12:28+00:00 hourly 0.9 https://trial.medpath.com/news/cannabis-compounds-show-promise-for-treating-liver-disease-affecting-one-third-of-adults 2026-03-10T09:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-restructures-operations-and-expands-biosimilar-pipeline-through-samsung-bioepis-partnership 2026-03-10T09:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/ards-clinical-pipeline-expands-with-50-companies-developing-novel-therapies 2026-03-10T05:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/kaist-researchers-develop-next-generation-mrna-platform-to-overcome-efficacy-loss-in-elderly-and-obese-patients 2026-03-10T05:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/ibio-s-ibio-610-shows-fat-selective-weight-loss-in-non-human-primate-study 2026-03-10T01:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/dobermann-trials-test-early-interventions-to-prevent-cardiogenic-shock-in-high-risk-ami-patients 2026-03-10T01:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-ipos-grow-larger-in-q1-2026-despite-slow-pace-raising-1-7-billion 2026-03-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/revive-therapeutics-expands-bucillamine-patent-portfolio-with-north-american-filings-for-chemical-warfare-agent-treatment 2026-03-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/intravascular-imaging-shows-sustained-clinical-benefits-at-5-years-in-complex-pci-procedures 2026-03-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/care-ventures-group-invests-in-ren-health-to-build-ai-powered-women-s-wellness-platform 2026-03-09T21:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/csl-invests-1-5-billion-to-expand-illinois-plasma-therapy-manufacturing-with-advanced-horizon-2-technology 2026-03-09T21:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-receives-fda-510-k-clearance-for-cloud-native-diagnostic-viewer 2026-03-09T21:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/brogidirsen-shows-sustained-motor-function-preservation-in-4-5-year-duchenne-muscular-dystrophy-trial 2026-03-09T21:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-koselugo-for-adult-neurofibromatosis-type-1-patients-with-plexiform-neurofibromas 2026-03-09T17:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/emalex-biosciences-initiates-expanded-access-program-for-novel-tourette-syndrome-therapy-ecopipam 2026-03-09T17:12:19+00:00 hourly 0.9 https://trial.medpath.com/news/verily-and-samsung-partner-to-integrate-galaxy-watch-8-data-into-clinical-research-platform 2026-03-09T17:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/medidata-and-menarini-group-expand-ai-powered-partnership-to-accelerate-oncology-clinical-trials 2026-03-09T17:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/crestone-s-crs3123-shows-superior-efficacy-in-phase-2-trial-for-c-difficile-infections 2026-03-09T17:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-completes-fda-pre-license-inspection-for-biosimilars-manufacturing-with-minor-procedural-observations 2026-03-09T17:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/inhaled-crispr-cas9-nanoparticles-target-sting1-in-alveolar-macrophages-to-reverse-pulmonary-fibrosis-in-mice 2026-03-09T17:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/junshi-biosciences-achieves-regulatory-milestone-with-first-domestic-subcutaneous-anti-pd-1-antibody-application-in-china 2026-03-09T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/novelmed-s-ruxoprubart-achieves-100-transfusion-independence-in-pnh-phase-ii-trial-gains-regulatory-clearance-for-subcutaneous-dosing 2026-03-09T17:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/lonza-and-genetix-extend-manufacturing-partnership-for-zynteglo-gene-therapy-amid-rising-patient-demand 2026-03-09T17:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-dental-dedicated-mri-system-following-successful-clinical-trial 2026-03-09T17:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/tme-pharma-secures-12-month-loan-extension-extends-cash-runway-to-q2-2027 2026-03-09T13:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/agilent-acquires-biocare-medical-for-950-million-to-expand-cancer-diagnostics-portfolio 2026-03-09T13:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/atamyo-therapeutics-reports-promising-early-results-for-ata-200-gene-therapy-in-rare-muscular-dystrophy 2026-03-09T13:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-completes-early-patient-enrollment-in-phase-3-trial-for-rare-neurodegenerative-disease-msa 2026-03-09T13:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/bioduro-and-cenra-form-strategic-joint-venture-to-strengthen-global-api-manufacturing-network 2026-03-09T13:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/kyron-bio-partners-with-servier-to-advance-precision-glycoengineering-for-next-generation-antibody-therapeutics 2026-03-09T13:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-and-kelun-biotech-receive-nmpa-approval-for-novel-bispecific-antibody-targeting-atopic-dermatitis 2026-03-09T13:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-secures-45-million-through-modified-licensing-agreement-with-healthcare-royalty-and-soleus-capital 2026-03-09T09:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/t-knife-therapeutics-receives-european-authorization-for-first-in-human-trial-of-crispr-edited-t-cell-therapy-tk-6302 2026-03-09T09:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/lifevac-becomes-first-fda-authorized-suction-anti-choking-device-for-emergency-airway-clearance 2026-03-09T05:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/dianthus-therapeutics-announces-interim-results-from-phase-3-captivate-trial-of-claseprubart-for-cidp 2026-03-09T01:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/nsw-government-expands-funding-for-cancer-clinical-trials-alliance-improving-patient-access-across-australia 2026-03-09T01:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/claritas-neurocloudtm-receives-anvisa-approval-for-ai-powered-brain-imaging-analysis-in-brazil 2026-03-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharmaceuticals-acquires-full-control-of-u-s-r-d-unit-with-36-million-investment-to-advance-cancer-pipeline 2026-03-08T21:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-completes-phase-3-trial-for-abp-206-opdivo-biosimilar-in-advanced-melanoma 2026-03-08T21:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/contineum-therapeutics-advances-pipe-791-phase-2-trial-for-idiopathic-pulmonary-fibrosis-with-differentiated-lpa1-receptor-targeting 2026-03-08T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/self-amplifying-rna-therapy-shows-promise-for-heart-attack-recovery-in-preclinical-studies 2026-03-08T17:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/cathworks-ffrangio-demonstrates-non-inferiority-to-invasive-pressure-wire-assessment-in-landmark-all-rise-trial 2026-03-08T01:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/ataibeckley-explores-2-billion-deal-for-psychedelic-depression-drug-as-deutsche-bank-sees-major-market-potential 2026-03-07T21:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/two-major-oncology-companies-terminate-early-stage-solid-tumor-trials 2026-03-07T21:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/novel-therapeutic-strategies-target-chemoresistance-mechanisms-in-small-cell-lung-cancer 2026-03-07T21:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/ono-pharmaceutical-expands-ai-driven-drug-discovery-into-neurology-and-immunology-through-strategic-partnerships 2026-03-07T10:45:13+00:00 hourly 0.9 https://trial.medpath.com/news/amarin-faces-revenue-decline-as-vascepa-confronts-generic-competition-in-us-market 2026-03-07T10:45:12+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-patient-with-advanced-nsclc-achieves-disease-stabilization-with-ivonescimab-in-china 2026-03-07T10:45:09+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-advances-novel-atac-technology-platform-with-multiple-cancer-candidates-in-clinical-development 2026-03-07T05:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/inmed-pharmaceuticals-winds-down-baymedica-operations-to-focus-on-cb1-cb2-receptor-drug-pipeline 2026-03-07T01:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/uk-government-establishes-world-first-regulatory-framework-for-space-manufactured-medicines 2026-03-07T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/hamlet-biopharma-signs-letter-of-intent-for-alpha-1h-bladder-cancer-therapy-partnership 2026-03-07T01:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/d-d-pharmatech-and-first-bio-secure-european-patent-for-novel-brain-disease-drug-nly02 2026-03-07T01:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/hypofractionated-radiotherapy-shows-promise-for-breast-cancer-treatment-with-reduced-treatment-time 2026-03-07T01:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/mindwalk-unveils-b-cell-llama-platform-for-next-generation-nanobody-discovery 2026-03-07T01:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lantheus-pylarify-truvu-for-enhanced-prostate-cancer-imaging 2026-03-07T01:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/aisa-pharma-s-aisa-021-shows-promise-in-phase-2-trial-for-systemic-sclerosis-associated-raynaud-s-phenomenon 2026-03-06T21:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/ketone-body-b-hydroxybutyrate-enhances-car-t-cell-therapy-efficacy-in-preclinical-studies-human-trials-underway 2026-03-06T21:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-clinical-trials-systematically-underreport-thromboembolic-risks-researchers-warn 2026-03-06T21:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-pfizer-ceacam5-adc-trial-halted-in-europe-as-merck-kgaa-advances-competing-asset-to-phase-3 2026-03-06T21:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/stpharm-initiates-nipah-virus-mrna-vaccine-production-for-korean-pandemic-preparedness-initiative 2026-03-06T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/servier-acquires-day-one-biopharmaceuticals-for-2-5-billion-to-strengthen-rare-oncology-portfolio 2026-03-06T17:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/diamedica-receives-health-canada-approval-for-phase-ii-preeclampsia-trial-of-dm199 2026-03-06T17:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/rowan-university-develops-first-robotic-system-for-minimally-invasive-long-bone-fracture-surgery 2026-03-06T17:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/ema-issues-first-eu-guidance-for-clinical-trials-during-public-health-emergencies 2026-03-06T17:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-executive-calls-for-fundamental-shift-in-clinical-trial-supply-models-amid-rising-market-pressures 2026-03-06T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-launches-clinical-trials-for-xafty-world-s-first-oral-antiviral-drug-for-dengue-fever-treatment 2026-03-06T13:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-patients-and-families-campaign-for-nhs-approval-of-zanidatamab-for-bile-duct-cancer 2026-03-06T13:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/exthera-medical-executive-pleads-guilty-to-concealing-patient-deaths-from-fda-in-blood-filtration-device-case 2026-03-06T05:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/capitello-281-trial-shows-capivasertib-plus-abiraterone-maintains-quality-of-life-in-pten-deficient-prostate-cancer 2026-03-06T05:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/cdt-equity-leverages-ai-platform-to-identify-rare-disease-drug-opportunities-across-multiple-therapeutic-areas 2026-03-06T01:15:59+00:00 hourly 0.9 https://trial.medpath.com/news/hopewell-therapeutics-sublicenses-tissue-targeting-lipid-nanoparticles-to-foxcroft-for-novel-cancer-vaccine-development 2026-03-06T01:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/lineage-cell-therapeutics-reports-positive-36-month-opregen-data-and-manufacturing-milestones-in-2025 2026-03-06T01:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-deepens-china-investment-with-eur170-million-manufacturing-expansion-and-drug-development-partnership 2026-03-06T01:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/inimmune-appoints-new-chief-medical-officer-and-head-of-financial-strategy-ahead-of-phase-2-allergic-rhinitis-data 2026-03-06T01:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/caredx-launches-vantx-ai-platform-for-transplant-data-analytics-and-announces-170m-lab-products-divestiture 2026-03-06T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-advances-kras-g12d-inhibitor-to-phase-3-despite-fatal-pneumonitis-and-european-clinical-hold 2026-03-06T01:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-achieves-remission-in-15-year-blood-cancer-patient-at-corewell-health 2026-03-06T01:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/bd-receives-ce-mark-approval-for-revello-vascular-covered-stent-to-treat-peripheral-artery-disease 2026-03-06T01:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/kestrel-therapeutics-receives-fda-clearance-for-pan-kras-inhibitor-kst-6051-phase-1-trial 2026-03-05T21:21:54+00:00 hourly 0.9 https://trial.medpath.com/news/quanta-therapeutics-direct-kras-inhibitors-show-promise-against-resistance-to-pan-ras-tri-complex-therapies 2026-03-05T21:21:08+00:00 hourly 0.9 https://trial.medpath.com/news/medincell-raises-capital-to-advance-long-acting-injectable-platform-and-expand-partnerships 2026-03-05T21:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/tangram-therapeutics-initiates-first-in-human-trial-of-tgm-312-for-mash-treatment 2026-03-05T21:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/fak-inhibition-unlocks-immune-response-against-treatment-resistant-ovarian-cancer 2026-03-05T21:14:50+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cells-from-baby-teeth-show-promise-for-treating-cerebral-palsy-in-clinical-and-preclinical-studies 2026-03-05T21:14:38+00:00 hourly 0.9 https://trial.medpath.com/news/cognito-therapeutics-secures-105-million-series-c-to-advance-at-home-alzheimer-s-device-toward-2027-launch 2026-03-05T21:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/lifecore-biomedical-expands-partnership-with-indomo-to-advance-at-home-acne-treatment-device 2026-03-05T17:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/bioxcel-s-bxcl501-shows-promise-in-phase-2-trial-for-opioid-withdrawal-treatment 2026-03-05T17:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/liberate-bio-secures-myeloid-optimized-car-design-licenses-to-advance-in-vivo-car-m-programs 2026-03-05T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/therna-partners-with-charles-river-to-develop-ai-designed-single-patient-rna-therapeutics-for-ultra-rare-diseases 2026-03-05T17:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/immatics-advances-prame-cell-therapy-anzu-cel-toward-2027-market-launch-with-strong-phase-3-enrollment 2026-03-05T17:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/immunis-secures-exclusive-license-for-novel-parkinson-s-dyskinesia-treatment-kora 2026-03-05T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-pharmaceutical-achieves-clinical-milestone-with-sirolimus-injection-for-rare-cancer-treatment 2026-03-05T17:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-receives-nclt-approval-for-subsidiary-merger-to-streamline-operations 2026-03-05T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-opens-bay-area-cryo-em-drug-discovery-center-to-accelerate-breakthrough-therapies 2026-03-05T17:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-study-shows-neoadjuvant-therapy-nearly-doubles-disease-free-survival-in-intrahepatic-cholangiocarcinoma 2026-03-05T17:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/science-corp-raises-230m-series-c-to-advance-prima-brain-computer-interface-for-vision-restoration 2026-03-05T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/seqster-launches-1-click-datalake-platform-to-transform-clinical-trial-design-and-recruitment 2026-03-05T17:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/early-automated-insulin-delivery-initiation-shows-superior-glycemic-control-in-youth-with-type-1-diabetes 2026-03-05T13:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-cognita-s-ai-powered-chest-x-ray-interpretation-system 2026-03-05T13:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-proposes-public-funding-for-letermovir-to-prevent-life-threatening-cmv-infections-after-stem-cell-transplants 2026-03-05T05:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/brazilian-single-dose-dengue-vaccine-shows-80-5-efficacy-against-hospitalization-in-five-year-phase-3-trial 2026-03-05T05:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/gossamer-bio-s-seralutinib-fails-phase-3-prosera-trial-due-to-stringent-statistical-threshold 2026-03-05T05:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/medidata-and-crio-partnership-delivers-near-perfect-data-accuracy-across-2500-global-clinical-trial-sites 2026-03-05T05:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/cytisinicline-shows-promise-for-smoking-cessation-even-in-treatment-resistant-patients-phase-3-data-reveals 2026-03-05T01:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/biovie-advances-phase-2-parkinson-s-disease-trial-with-bezisterim-targeting-neuroinflammation-and-insulin-resistance 2026-03-05T01:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-drug-zorevunersen-shows-up-to-91-seizure-reduction-in-children-with-dravet-syndrome 2026-03-05T01:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/cordenpharma-colorado-expands-peptide-development-capabilities-with-64000-square-foot-leed-gold-facility-at-flatiron-park 2026-03-04T21:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/immunoscape-s-novel-seed-and-boost-platform-achieves-100-survival-in-ovarian-cancer-model-advances-to-clinical-trial 2026-03-04T21:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biological-launches-antigens-for-2026-2027-influenza-vaccine-strains-following-who-recommendations 2026-03-04T21:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/nervgen-pharma-strengthens-leadership-team-with-key-regulatory-and-patient-advocacy-appointments 2026-03-04T21:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/cordis-launches-selution-slr-drug-eluting-balloon-in-japan-with-strong-three-year-clinical-data 2026-03-04T21:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/bryet-files-ind-application-for-ml-016-oncology-therapy-targeting-advanced-solid-tumors 2026-03-04T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-novel-therapeutic-strategy-for-rett-syndrome-through-alternative-splicing-modulation 2026-03-04T21:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/stryker-launches-mako-rps-handheld-robotic-system-for-total-knee-replacement-surgery 2026-03-04T21:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/an2-therapeutics-expands-epetraborole-development-into-phase-2-trial-for-polycythemia-vera 2026-03-04T17:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-successfully-transitions-live-phase-i-oncology-trial-from-manual-processes-to-automated-rtsm-system 2026-03-04T17:29:44+00:00 hourly 0.9 https://trial.medpath.com/news/alithea-genomics-secures-8-9m-to-scale-rna-sequencing-technology-for-drug-discovery 2026-03-04T17:29:24+00:00 hourly 0.9 https://trial.medpath.com/news/vericel-secures-fda-approval-for-advanced-cell-therapy-manufacturing-facility-to-expand-maci-production 2026-03-04T17:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/inovio-and-akeso-partner-to-test-novel-dna-bispecific-antibody-combination-for-glioblastoma-treatment 2026-03-04T17:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-ai-enabled-imaging-device-for-breast-cancer-surgery-margin-assessment 2026-03-04T17:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-immunotherapy-for-recurrent-respiratory-papillomatosis-offering-hope-for-rare-voice-threatening-disease 2026-03-04T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/novabridge-s-vis-101-shows-promising-phase-2a-results-in-wet-amd-with-potential-best-in-class-durability 2026-03-04T13:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-secures-1-1b-license-for-antengene-s-masked-t-cell-engager-atg-201-in-autoimmune-disease-push 2026-03-04T13:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/theolytics-secures-eur8-million-eu-grant-to-advance-novel-oncolytic-immunotherapy-for-platinum-resistant-ovarian-cancer 2026-03-04T13:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/roche-commits-520-million-investment-to-establish-south-korea-as-asian-clinical-trial-hub 2026-03-04T05:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/genevant-sciences-and-arbutus-biopharma-secure-2-25-billion-settlement-with-moderna-over-covid-19-vaccine-patent-infringement 2026-03-04T01:04:39+00:00 hourly 0.9 https://trial.medpath.com/news/teva-secures-400-million-from-blackstone-to-advance-tl1a-targeting-antibody-for-ibd-treatment 2026-03-04T01:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-generic-fluticasone-propionate-inhaler-with-180-day-market-exclusivity 2026-03-04T01:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-de-novo-clearance-to-ai-powered-ultrasound-technology-for-predicting-delivery-dates 2026-03-04T01:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/cour-pharma-s-cnp-104-shows-sustained-liver-function-improvements-in-primary-biliary-cholangitis-one-year-study 2026-03-03T21:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-pbpk-modeling-to-replace-ten-clinical-trials-for-cml-drug-asciminib 2026-03-03T21:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/creatv-bio-s-lifetracdx-blood-test-supports-cytodyn-s-phase-2-colorectal-cancer-trial 2026-03-03T21:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/sihuan-pharmaceutical-s-bireociclib-receives-nmpa-approval-for-first-line-hr-her2-advanced-breast-cancer-treatment 2026-03-03T21:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/implanet-secures-fda-clearance-for-3d-printed-swingo-cervical-spine-cage 2026-03-03T21:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-and-liquid-ai-launch-lightweight-ai-model-for-on-premise-drug-discovery 2026-03-03T21:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/yank-technologies-secures-2m-u-s-army-contract-for-wireless-charging-technology-development 2026-03-03T21:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/reprocell-launches-fda-compliant-gmp-manufacturing-platform-for-clinical-ipscs 2026-03-03T21:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/isct-and-jsrm-launch-five-year-strategic-partnership-to-advance-ipsc-based-therapies-globally 2026-03-03T21:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/mount-sinai-and-king-saud-university-launch-three-year-precision-medicine-initiative-for-familial-ibd 2026-03-03T17:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/antiverse-raises-9-3m-series-a-to-develop-ai-designed-antibodies-for-challenging-disease-targets 2026-03-03T17:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/cirrus-therapeutics-expands-to-singapore-unveils-novel-rpe-cell-therapy-for-geographic-atrophy 2026-03-03T17:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/aspen-pharmacare-targets-canadian-market-entry-with-generic-ozempic-by-q3-2024 2026-03-03T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/antiverse-secures-9-3m-series-a-to-advance-ai-powered-antibody-discovery-platform 2026-03-03T17:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/quell-therapeutics-launches-phase-1-2-trial-of-novel-car-treg-therapy-for-autoimmune-diseases 2026-03-03T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/hepion-pharmaceuticals-in-licenses-novel-ctrna-biomarker-assay-for-early-hepatocellular-carcinoma-detection 2026-03-03T17:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/northsea-therapeutics-secures-orphan-drug-designations-for-orziloben-in-rare-liver-disease 2026-03-03T17:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/adela-s-blood-based-test-shows-strong-predictive-power-for-immunotherapy-response-in-advanced-solid-tumors 2026-03-03T17:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/splisense-receives-ema-e-prime-designation-for-spl84-antisense-therapy-in-cystic-fibrosis 2026-03-03T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-juxtapid-for-pediatric-patients-with-homozygous-familial-hypercholesterolemia 2026-03-03T17:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/syntis-bio-doses-first-patient-in-phase-1-1b-trial-of-novel-oral-obesity-treatment-synt-101 2026-03-03T17:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/progeria-research-foundation-partners-with-forge-biologics-to-advance-crispr-gene-therapy-for-rare-aging-disease 2026-03-03T17:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/theravance-biopharma-s-phase-3-cypress-study-fails-primary-endpoint-company-winds-down-ampreloxetine-program 2026-03-03T17:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-harrow-s-phase-3-trial-for-triesence-in-cataract-surgery-patients 2026-03-03T17:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/growth-hormone-receptor-emerges-as-promising-target-for-therapy-resistant-lung-cancer 2026-03-03T17:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/sanaregen-vision-therapeutics-receives-fda-clearance-for-phase-i-ii-trial-of-cell-therapy-for-familial-drusen 2026-03-03T17:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/ataibeckley-advances-bpl-003-to-phase-3-trials-for-treatment-resistant-depression-following-fda-approval 2026-03-03T13:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/secarna-pharmaceuticals-expands-ai-powered-oligonucleotide-partnership-with-curie-bio 2026-03-03T13:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/senhwa-biosciences-partners-with-ai-biotech-celltype-to-transform-cx-4945-into-next-generation-immunotherapy-platform 2026-03-03T13:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/hua-medicine-s-first-in-class-diabetes-drug-dorzagliatin-gains-hong-kong-approval-marking-international-expansion-milestone 2026-03-03T13:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/snipr-s-crispr-armed-phage-therapy-snipr001-demonstrates-safety-in-first-human-trial 2026-03-03T09:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/congruence-therapeutics-and-ono-pharmaceutical-expand-partnership-to-target-neurology-and-immunology-programs 2026-03-03T01:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/two-major-cannabinoid-companies-achieve-european-cep-certification-for-pharmaceutical-grade-cbd 2026-03-02T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/argo-biopharma-strengthens-leadership-with-appointment-of-dr-gena-wang-as-cfo-and-chief-strategy-officer 2026-03-02T21:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-lithium-shows-promise-in-slowing-verbal-memory-decline-in-mild-cognitive-impairment 2026-03-02T21:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/monopar-therapeutics-strengthens-leadership-team-ahead-of-alxn1840-nda-submission-for-wilson-disease 2026-03-02T21:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/imviva-s-allogeneic-car-t-therapy-cta313-achieves-100-response-rate-in-systemic-lupus-erythematosus-trial 2026-03-02T17:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/bioatla-initiates-strategic-review-process-amid-major-restructuring-and-70-workforce-reduction 2026-03-02T17:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/xellsmart-secures-fourth-consecutive-fda-and-nmpa-approval-for-ipsc-cell-therapy-targeting-rare-neurodegenerative-disease-msa-p 2026-03-02T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/early-phase-clinical-trial-outsourcing-market-projected-to-reach-14-8-billion-by-2030-driven-by-personalized-medicine-growth 2026-03-02T17:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/revir-therapeutics-initiates-phase-1-trial-of-rtx-117-for-rare-neurological-diseases 2026-03-02T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/gyre-therapeutics-acquires-cullgen-for-300m-to-expand-protein-degradation-platform 2026-03-02T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/rallybio-and-candid-therapeutics-announce-505-million-merger-to-advance-t-cell-engager-pipeline-for-autoimmune-diseases 2026-03-02T17:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/longbio-s-lp-003-demonstrates-superior-efficacy-over-xolair-in-phase-ii-chronic-urticaria-trial 2026-03-02T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-skyrizi-demonstrates-superior-efficacy-in-phase-3-crohn-s-disease-trial-with-subcutaneous-induction 2026-03-02T17:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/pvp-labs-taphalgin-receives-dea-non-controlled-substance-designation-advancing-non-addictive-pain-management 2026-03-02T17:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/bd-receives-fda-clearance-for-first-1000ml-antimicrobial-irrigation-system-for-powered-surgical-lavage 2026-03-02T17:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-receives-fda-tentative-approval-for-first-generic-version-of-lutathera-for-neuroendocrine-tumors 2026-03-02T17:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/talphera-reaches-50-enrollment-in-nafamostat-crrt-trial-targets-2026-fda-filing 2026-03-02T17:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/elutia-appoints-pete-ligotti-as-cco-to-lead-nxt-41x-commercial-launch-in-1-5b-breast-reconstruction-market 2026-03-02T17:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/avenacy-launches-generic-diphenhydramine-injectable-marking-26th-product-since-2023-inception 2026-03-02T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/alaunos-therapeutics-reports-promising-preclinical-data-for-non-hormonal-obesity-drug-aln1003 2026-03-02T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/turkish-universities-launch-clinical-trials-for-domestically-produced-car-t-cell-therapy-against-blood-cancers 2026-03-02T13:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/bimagrumab-semaglutide-combination-achieves-superior-weight-loss-with-preserved-muscle-mass-in-obesity-trial 2026-03-02T13:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-ralinepag-achieves-55-risk-reduction-in-pivotal-pah-trial-paving-way-for-fda-submission 2026-03-02T13:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/tolemy-bio-secures-eur1-4m-to-develop-ai-powered-cell-biology-platform-for-therapeutic-manufacturing 2026-03-02T09:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-s-paradise-ultrasound-renal-denervation-system-gains-insurance-coverage-in-japan-for-resistant-hypertension 2026-03-02T09:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/jingfang-medicine-s-gfh375-receives-china-s-first-breakthrough-therapy-designation-for-kras-g12d-mutated-nsclc 2026-03-02T05:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/roquefort-therapeutics-acquires-tacc3-inhibitor-ao-252-in-ps31-9m-deal-rebrands-as-coiled-therapeutics 2026-03-02T05:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/xenon-pharmaceuticals-epilepsy-drug-azetukalner-achieves-record-breaking-trial-results-paving-way-for-fda-approval 2026-03-02T01:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-chicago-develops-targeted-mrna-nanoparticle-system-to-prevent-type-1-diabetes-progression 2026-03-01T21:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/himalaya-trial-5-year-data-shows-durable-survival-benefit-for-stride-regimen-in-advanced-hepatocellular-carcinoma 2026-03-01T17:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/leap-therapeutics-secures-new-funding-through-royalty-deal-as-dkn-01-advances-in-oncology-trials 2026-03-01T17:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/ssy-group-secures-first-in-china-approval-for-fat-soluble-vitamin-injection-expands-medical-device-portfolio 2026-03-01T17:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/caplin-steriles-secures-fda-approval-for-generic-desmopressin-injection-in-26-million-market 2026-03-01T17:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/n4-pharma-pivots-to-rna-therapeutics-with-new-ceo-and-thalia-therapeutics-rebrand 2026-03-01T17:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/hiv-cure-trial-shows-54-of-placebo-recipients-achieve-prolonged-viral-remission-after-receiving-experimental-therapy 2026-03-01T16:51:19+00:00 hourly 0.9 https://trial.medpath.com/news/innocan-pharma-receives-third-consecutive-fda-fee-waiver-for-cannabidiol-based-pain-treatment-in-dogs 2026-03-01T16:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/biocytogen-reaches-clinical-milestone-as-first-patient-dosed-in-ideaya-s-b7h3-ptk7-bispecific-adc-phase-1-trial 2026-03-01T16:43:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-biomarin-s-palynziq-for-adolescents-with-pku-expanding-treatment-access-to-ages-12-and-older 2026-03-01T16:42:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-novo-nordisk-s-sogroya-for-three-additional-pediatric-growth-disorders 2026-02-28T01:01:55+00:00 hourly 0.9 https://trial.medpath.com/news/one-third-of-rheumatologists-view-bristol-myers-squibb-s-sotyktu-as-substantial-advance-for-psoriatic-arthritis-ahead-of-march-6-fda-decision 2026-02-27T21:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/gallant-partners-with-mwi-animal-health-to-establish-first-ultra-low-temperature-cold-chain-for-veterinary-stem-cell-therapy 2026-02-27T21:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/flare-therapeutics-reports-promising-phase-1a-results-for-first-in-class-pparg-inhibitor-fx-909-in-advanced-urothelial-cancer 2026-02-27T17:12:46+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-technologies-to-present-phase-1-neo212-01-dose-escalation-results-for-cns-cancer-treatment 2026-02-27T17:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/blue-jet-healthcare-announces-2300-crore-pharmaceutical-manufacturing-facility-in-andhra-pradesh 2026-02-27T17:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/ema-accepts-marketing-authorization-application-for-cevira-first-in-class-photodynamic-therapy-for-cervical-lesions 2026-02-27T17:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/ema-approves-first-single-dose-oral-treatment-for-african-sleeping-sickness 2026-02-27T17:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-diverge-on-alzheimer-s-drug-approvals-as-italy-halts-reimbursement 2026-02-27T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/opko-health-advances-modex-pipeline-with-five-clinical-programs-and-merck-ebv-vaccine-partnership 2026-02-27T06:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/synthekine-partners-with-merck-to-evaluate-stk-012-combination-therapy-in-phase-2-nsclc-trial 2026-02-27T05:02:36+00:00 hourly 0.9 https://trial.medpath.com/news/evox-therapeutics-partners-with-rett-syndrome-research-trust-to-advance-exoedit-gene-editing-platform-for-neurological-disease 2026-02-27T01:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/arna-pharma-and-slate-run-pharmaceuticals-form-joint-venture-to-create-scaled-u-s-specialty-pharmaceutical-platform 2026-02-27T01:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-stem-cell-therapy-for-spina-bifida-shows-safety-in-groundbreaking-fetal-surgery-trial 2026-02-27T01:01:11+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-xofigo-plus-enzalutamide-reduces-death-risk-by-24-in-metastatic-prostate-cancer-trial 2026-02-26T21:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/ose-immunotherapeutics-receives-second-positive-idmc-recommendation-for-phase-3-artemia-trial-of-tedopi-r-in-nsclc 2026-02-26T21:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-in-hampton-roads-receives-tricvalve-implant-in-fda-breakthrough-device-trial-for-severe-tricuspid-regurgitation 2026-02-26T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/tecovirimat-fails-to-show-efficacy-against-mpox-in-landmark-stomp-trial 2026-02-26T21:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/ella-ai-health-advocate-receives-irb-exemption-advancing-ethical-clinical-trial-recruitment 2026-02-26T21:01:34+00:00 hourly 0.9 https://trial.medpath.com/news/chop-and-penn-medicine-develop-first-crispr-platform-for-direct-analysis-of-patient-aml-cells 2026-02-26T21:01:34+00:00 hourly 0.9 https://trial.medpath.com/news/endra-s-taeus-liver-device-achieves-mri-level-consistency-in-masld-clinical-study 2026-02-26T17:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/pmv-pharma-s-rezatapopt-shows-promise-in-first-in-human-study-for-tp53-y220c-mutated-solid-tumors 2026-02-26T17:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-acquires-sitryx-s-novel-oral-immunometabolic-program-in-500m-deal 2026-02-26T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/kairos-pharma-signs-term-sheet-to-acquire-two-clinical-stage-lung-cancer-assets-from-celyn-therapeutics 2026-02-26T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/gemmabio-doses-first-patient-in-phase-1-2-trial-of-next-generation-gene-therapy-gb221-for-spinal-muscular-atrophy-type-1 2026-02-26T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/quotient-sciences-expands-manufacturing-partnership-with-ipsen-for-ultra-rare-fop-treatment 2026-02-26T17:02:44+00:00 hourly 0.9 https://trial.medpath.com/news/asahi-kasei-acquires-german-antiviral-specialist-aicuris-for-eur780-million-to-expand-infectious-disease-portfolio 2026-02-26T17:02:23+00:00 hourly 0.9 https://trial.medpath.com/news/samchundang-secures-4-billion-european-glp-1-deal-with-breakthrough-patent-circumventing-technology 2026-02-26T13:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/hotspot-therapeutics-demonstrates-promising-preclinical-results-for-novel-irf5-inhibitors-in-autoimmune-disease-treatment 2026-02-26T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/curanex-pharmaceuticals-completes-gmp-manufacturing-milestone-for-ulcerative-colitis-drug-candidate-phyto-n 2026-02-26T09:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-technology-development-board-funds-indigenous-car-nk-cell-therapy-platform-for-cancer-and-leishmaniasis-treatment 2026-02-26T09:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-linerixibat-receives-priority-review-in-china-for-rare-liver-disease-related-pruritus 2026-02-26T09:01:40+00:00 hourly 0.9 https://trial.medpath.com/news/spectral-medical-s-tigris-trial-shows-significant-mortality-reduction-in-endotoxic-septic-shock-published-in-the-lancet 2026-02-26T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/mahzi-therapeutics-doses-first-patient-in-groundbreaking-gene-therapy-trial-for-pitt-hopkins-syndrome 2026-02-26T05:03:34+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-surgical-acquires-j-j-s-neuwave-medical-to-expand-robotic-cancer-treatment-platform 2026-02-26T05:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/b-c-teen-becomes-first-patient-cured-of-chronic-granulomatous-disease-using-prime-editing-gene-therapy 2026-02-26T05:01:44+00:00 hourly 0.9 https://trial.medpath.com/news/novel-p53-targeting-drug-rezatapopt-shows-20-response-rate-in-phase-1-trial-across-multiple-cancer-types 2026-02-26T01:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-numelvi-first-second-generation-jak-inhibitor-for-canine-allergic-dermatitis 2026-02-26T01:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/optimi-health-launches-ibogaine-initiative-following-u-s-executive-order-on-psychedelic-drug-development 2026-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/melodia-therapeutics-secures-key-u-s-patent-for-novel-dpp1-inhibitor-mld-151 2026-02-25T21:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/leveragen-secures-japanese-patent-for-singularity-platform-single-domain-antibody-discovery-technology 2026-02-25T21:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/nexus-precision-health-acquires-leal-health-to-scale-ai-powered-precision-medicine-platform 2026-02-25T21:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-oral-liquid-desmopressin-solution-for-central-diabetes-insipidus 2026-02-25T21:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/alkermes-ceo-richard-pops-to-retire-after-35-year-leadership-blair-jackson-named-successor 2026-02-25T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/breezebio-raises-60m-series-b-to-advance-precision-genetic-medicine-platform-and-type-1-diabetes-therapy 2026-02-25T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/cumberland-pharmaceuticals-launches-national-promotion-of-talicia-for-h-pylori-treatment 2026-02-25T17:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/slate-medicines-secures-130m-series-a-to-advance-novel-anti-pacap-migraine-therapy 2026-02-25T17:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/itm-to-present-pancreatic-neuroendocrine-tumor-subgroup-analysis-from-phase-3-compete-trial-at-enets-2026 2026-02-25T17:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-secures-patent-victory-as-abbvie-withdraws-challenge-following-1-2-billion-gilgamesh-acquisition 2026-02-25T17:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-acquires-charles-river-discovery-assets-to-expand-ai-driven-drug-development-platform 2026-02-25T17:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/precisionlife-and-ovation-develop-first-genetic-biomarkers-to-predict-glp-1-therapy-response 2026-02-25T17:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-viatris-supplemental-application-for-phentolamine-eye-drops-to-treat-presbyopia 2026-02-25T17:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-acquires-35pharma-for-950m-to-advance-potential-best-in-class-pulmonary-hypertension-treatment-hs235 2026-02-25T13:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/northx-biologics-and-demeetra-form-strategic-partnership-to-accelerate-biologics-development-from-gene-to-gmp-manufacturing 2026-02-25T13:02:45+00:00 hourly 0.9 https://trial.medpath.com/news/turkish-scientists-develop-computational-digital-scalpel-to-accelerate-drug-discovery-through-protein-allosteric-site-targeting 2026-02-25T13:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/pentixapharm-receives-fda-approval-for-cxcr4-targeted-radiotheranostic-program-in-blood-cancers 2026-02-25T13:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/solascure-s-aurase-wound-gel-shows-22x-better-debridement-and-7x-faster-healing-in-chronic-wounds 2026-02-25T13:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/george-medicines-expands-global-reach-of-triple-combination-hypertension-drug-gmrx2-through-strategic-licensing-deals 2026-02-25T12:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/steincares-and-shilpa-biologicals-form-strategic-partnership-to-expand-biosimilar-access-across-latin-america 2026-02-25T09:02:36+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-doravirine-islatravir-combination-demonstrates-non-inferiority-in-phase-3-hiv-treatment-trials 2026-02-25T05:02:03+00:00 hourly 0.9 https://trial.medpath.com/news/turbine-raises-25-million-series-b-to-expand-ai-powered-virtual-biology-platform-into-immunology 2026-02-25T01:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-seeks-fda-approval-for-first-ever-treatment-of-rare-blood-disorder-waiha 2026-02-25T01:01:36+00:00 hourly 0.9 https://trial.medpath.com/news/polaroid-therapeutics-receives-ce-mark-for-novel-antimicrobial-wound-dressing-poltx-fiber 2026-02-25T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/honeywell-reduces-johnson-matthey-catalyst-technologies-acquisition-by-640-million 2026-02-25T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/nih-funded-trial-achieves-70-reduction-in-hiv-incidence-through-digital-health-innovation-in-rural-east-africa 2026-02-24T21:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-researchers-engineer-t-cells-to-overcome-glucose-starvation-in-solid-tumors-using-cellobiose-metabolism 2026-02-24T21:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/arpa-h-awards-144-million-to-accelerate-human-healthspan-trials-targeting-aging-biology 2026-02-24T21:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/cosmos-health-strengthens-ai-drug-discovery-platform-with-appointment-of-athos-therapeutics-ceo-dr-dimitrios-iliopoulos 2026-02-24T21:02:44+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-biosciences-reports-clinical-progress-across-three-drug-pipeline-in-2025 2026-02-24T17:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-publishes-variant-agnostic-covid-19-protection-model-for-monoclonal-antibody-pemivibart 2026-02-24T17:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/azitra-expands-atr-04-clinical-trial-to-md-anderson-cancer-center-for-egfr-inhibitor-associated-rash-treatment 2026-02-24T17:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/treace-medical-presents-positive-clinical-data-for-3d-bunion-correction-technologies-at-acfas-2026 2026-02-24T17:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/centauri-therapeutics-secures-ps6m-from-amr-action-fund-to-advance-novel-antibiotic-ctx-187-through-phase-i-trials 2026-02-24T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/bloom-science-initiates-phase-1b-obesity-trial-of-bl-001-advancing-ketogenic-based-alternative-to-glp-1-therapies 2026-02-24T17:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/promatix-biosciences-reports-50-fold-potency-improvement-with-novel-bispecific-adc-for-colorectal-cancer 2026-02-24T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/onemednet-partners-with-risorius-to-advance-eeg-based-digital-biomarkers-for-cns-research 2026-02-24T17:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/vico-therapeutics-advances-vo659-with-twice-annual-dosing-in-phase-1-2-trial-for-huntington-s-disease-and-spinocerebellar-ataxias 2026-02-24T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/cf-pharmtech-receives-nmpa-acceptance-for-first-in-class-inhaled-pulmonary-fibrosis-treatment-icf004 2026-02-24T17:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/us-and-japan-maintain-stricter-alzheimer-s-drug-approval-standards-compared-to-global-markets 2026-02-24T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/cansino-biologics-secures-nmpa-approval-to-expand-menhycia-mcv4-vaccine-to-children-up-to-6-years-old 2026-02-24T17:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/edesa-biotech-s-paridiprubart-shows-27-mortality-reduction-in-phase-3-ards-study 2026-02-24T17:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/solascure-s-aurase-wound-gel-demonstrates-22x-faster-debridement-in-phase-ii-chronic-wound-trial 2026-02-24T17:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/slate-medicines-raises-130m-to-develop-novel-pacap-targeting-migraine-drug 2026-02-24T17:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/molnupiravir-demonstrates-77-efficacy-against-feline-infectious-peritonitis-in-clinical-trial 2026-02-24T17:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-designation-to-orthonika-s-synthetic-total-meniscus-implant 2026-02-24T13:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/almirall-advances-etherna-s-intratumoral-mrna-therapy-lad116-to-clinical-development-for-non-melanoma-skin-cancer 2026-02-24T09:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/hif-2a-inhibitor-casdatifan-demonstrates-15-month-progression-free-survival-in-advanced-kidney-cancer 2026-02-24T05:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/smith-nephew-partners-with-si-bone-to-expand-pelvic-fracture-fixation-portfolio 2026-02-24T05:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/rytvela-shows-40-reduction-in-preterm-birth-rates-in-preclinical-study 2026-02-24T05:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-partial-clinical-hold-on-macrogenics-lorigerlimab-trial-following-severe-safety-events 2026-02-24T05:04:53+00:00 hourly 0.9 https://trial.medpath.com/news/kyntra-bio-s-fg-3246-adc-shows-promising-results-in-metastatic-prostate-cancer-combination-trial 2026-02-24T01:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-and-vir-biotechnology-form-1-7-billion-strategic-partnership-for-psma-targeting-t-cell-engager-vir-5500-in-prostate-cancer 2026-02-24T01:01:41+00:00 hourly 0.9 https://trial.medpath.com/news/grove-biopharma-s-protein-like-polymers-successfully-degrade-undruggable-cancer-targets-myc-and-kras 2026-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-sues-johnson-johnson-over-allegedly-false-prostate-cancer-drug-marketing-claims 2026-02-23T21:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/viiv-s-dovato-shows-lower-steatotic-liver-disease-risk-compared-to-biktarvy-in-hiv-patients 2026-02-23T21:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-allurion-swallowable-gastric-balloon-for-obesity-treatment 2026-02-23T21:02:13+00:00 hourly 0.9 https://trial.medpath.com/news/uk-mhra-approves-first-ever-treatment-for-non-cystic-fibrosis-bronchiectasis 2026-02-23T21:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/dare-bioscience-receives-fda-clearance-for-phase-2-trial-of-dare-hpv-first-potential-treatment-for-persistent-high-risk-hpv-infection 2026-02-23T17:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/blackstone-life-sciences-partners-with-johnson-johnson-to-advance-bleximenib-for-acute-myeloid-leukemia-treatment 2026-02-23T17:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/angelini-pharma-partners-with-quiver-bioscience-in-120m-deal-to-advance-ai-driven-therapies-for-rare-genetic-epilepsies 2026-02-23T17:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/surenano-science-acquires-glucapharm-advancing-second-generation-glp-1-drug-gep44-with-improved-tolerability 2026-02-23T17:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/generate-biomedicines-targets-2-2-billion-valuation-in-ipo-as-ai-drug-discovery-platform-advances-severe-asthma-therapy 2026-02-23T17:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/checkpoint-inhibitors-show-promise-for-hiv-positive-cancer-patients-across-multiple-studies 2026-02-23T17:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/bioxytran-partners-with-university-of-georgia-to-test-novel-h5n1-bird-flu-treatment 2026-02-23T17:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/transcode-therapeutics-publishes-breakthrough-rig-i-agonist-study-enabling-tumor-selective-cancer-immunotherapy 2026-02-23T17:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/alps-group-reports-positive-safety-data-for-autologous-nk-cell-therapy-in-nine-patient-case-series 2026-02-23T17:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/eu-launches-eur225-million-initiative-to-accelerate-next-generation-influenza-vaccine-development 2026-02-23T13:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/morepen-laboratories-secures-91-million-cdmo-contract-from-global-pharmaceutical-company 2026-02-23T09:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/uk-government-launches-ps100m-funding-initiative-to-strengthen-life-sciences-manufacturing-and-r-d-competitiveness 2026-02-23T07:28:22+00:00 hourly 0.9 https://trial.medpath.com/news/virion-therapeutics-vron-0200-shows-sustained-anti-hbv-immunity-in-phase-1b-trial 2026-02-23T01:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/neptune-medical-s-triton-robot-achieves-100-cecal-intubation-rate-in-first-in-human-colonoscopy-study 2026-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/til-therapy-expands-access-across-us-health-systems-following-fda-approval-for-advanced-melanoma 2026-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gyder-surgical-s-pin-less-hip-navigation-system-debuts-in-us-commercial-surgery 2026-02-22T21:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/redmile-group-invests-49-million-in-scholar-rock-as-apitegromab-nears-regulatory-resubmission 2026-02-22T21:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-demonstrates-cannabis-extract-ver-01-significantly-reduces-chronic-low-back-pain 2026-02-22T17:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/brazil-india-partnership-advances-pertuzumab-development-for-her-2-metastatic-breast-cancer 2026-02-22T13:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-targets-10000-metric-tonnes-annual-penicillin-g-production-amid-government-policy-support 2026-02-22T09:01:20+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-completes-phase-2-trial-of-biib091-for-relapsing-multiple-sclerosis 2026-02-21T22:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-shows-promise-for-alcohol-use-disorder-treatment-in-preclinical-study 2026-02-21T12:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-completes-comprehensive-audit-of-90-of-india-s-cough-syrup-manufacturers-following-safety-concerns 2026-02-21T12:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-pauses-pathways-clinical-trial-following-safety-concerns-for-children-and-young-people 2026-02-21T04:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/enhanced-car-nk-cell-therapy-shows-superior-tumor-control-through-novel-costimulatory-design 2026-02-20T21:03:24+00:00 hourly 0.9 https://trial.medpath.com/news/adarx-pharmaceuticals-to-present-phase-1-2-data-for-onvuzosiran-sirna-therapy-at-aaaai-2026-meeting 2026-02-20T21:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/telefonica-vithas-and-ufv-pioneer-quantum-computing-for-cancer-drug-discovery-targeting-braf-v600e-mutation 2026-02-20T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/gvrp-and-yurogen-biosystems-form-strategic-partnership-to-advance-antibody-discovery-in-india 2026-02-20T17:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-world-s-first-ips-cell-based-therapies-for-parkinson-s-disease-and-heart-failure 2026-02-20T17:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/insufficient-source-material-for-roche-leukemia-treatment-fda-approval 2026-02-20T17:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-gras-approval-for-rubisco-protein-as-plantible-foods-advances-lemna-based-ingredient 2026-02-20T14:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/milken-institute-and-ann-theodore-foundation-launch-575000-grant-for-mtor-inhibitor-trial-in-cutaneous-sarcoidosis 2026-02-20T14:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/southampton-researchers-launch-clinical-trial-using-diagnostic-tampons-for-early-ovarian-cancer-detection 2026-02-20T14:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-launches-japan-s-first-gene-therapy-for-duchenne-muscular-dystrophy 2026-02-20T09:02:31+00:00 hourly 0.9 https://trial.medpath.com/news/prothena-reports-q4-2025-results-as-neurodegeneration-pipeline-advances-with-major-partnerships 2026-02-20T05:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/starton-therapeutics-initiates-phase-2a-trial-of-star-lld-for-relapsed-refractory-multiple-myeloma 2026-02-20T05:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/indian-regulatory-committee-recommends-dpco-exemption-for-first-indigenous-antibiotic-nafithromycin 2026-02-20T05:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/former-novartis-cmo-john-tsai-appointed-global-head-of-r-d-at-daiichi-sankyo 2026-02-20T05:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-validates-firstgene-r-prenatal-screen-with-exceptional-accuracy-across-multiple-testing-components 2026-02-20T01:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/xenon-pharmaceuticals-faces-critical-phase-3-data-readout-for-epilepsy-drug-azetukalner-in-march 2026-02-20T01:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-explores-20-billion-sale-of-depuy-synthes-orthopedics-unit 2026-02-20T01:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-files-patent-lawsuit-against-moderna-over-next-generation-covid-19-vaccine-technology 2026-02-20T01:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/next-life-sciences-advances-two-non-hormonal-male-contraceptives-into-phase-ii-clinical-trials 2026-02-20T01:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/pylarify-becomes-first-blockbuster-radiodiagnostic-with-1-06-billion-in-2024-sales 2026-02-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/stereotactic-radiation-improves-quality-of-life-for-patients-with-multiple-brain-metastases 2026-02-19T21:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/step-pharma-receives-eur2-5-million-eic-grant-to-advance-ctps1-inhibitor-dencatistat-for-gynecological-cancers 2026-02-19T21:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/xeris-biopharma-files-patent-infringement-lawsuit-to-protect-recorlev-against-generic-competition 2026-02-19T21:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-ag-completes-exit-from-indian-operations-with-345-million-stake-sale-to-investment-consortium 2026-02-19T21:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/chryscapital-acquires-majority-stake-in-novartis-india-for-rs-1450-crore 2026-02-19T21:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-partners-with-niper-raebareli-to-advance-pharmaceutical-research-and-education-in-india 2026-02-19T21:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/lario-therapeutics-secures-2-4m-to-advance-neuronal-calcium-channel-platform-for-parkinson-s-and-ptsd 2026-02-19T21:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/omvoh-demonstrates-three-year-steroid-free-remission-in-crohn-s-disease-patients 2026-02-19T21:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-s-entyvio-shows-promise-in-pediatric-ulcerative-colitis-with-47-remission-rate-in-phase-3-kepler-trial 2026-02-19T21:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/nexeos-bio-receives-fda-clearance-for-phase-ii-iii-trial-of-ntx-1024-in-rare-eye-disease 2026-02-19T21:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-age-range-for-staar-surgical-s-evo-icl-to-include-patients-up-to-60-years-old 2026-02-19T21:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/altesa-biosciences-secures-75-million-series-b-to-advance-first-in-class-copd-exacerbation-treatment 2026-02-19T17:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-launches-patent-infringement-case-against-johnson-johnson-over-car-t-cell-therapy-in-europe 2026-02-19T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/rituxan-receives-japanese-approval-for-autoimmune-hemolytic-anemia-treatment 2026-02-19T17:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/klothea-bio-launches-phase-1b-trial-of-akl003-mrna-therapy-targeting-longevity-protein-klotho 2026-02-19T17:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/ten63-therapeutics-raises-45m-to-advance-ai-driven-drug-discovery-platform-targeting-previously-undruggable-proteins 2026-02-19T17:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/kilgourmd-hair-loss-system-shows-rapid-results-in-menopausal-women-clinical-trial 2026-02-19T17:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/breath-diagnostics-receives-fda-breakthrough-device-designation-for-onebreath-platform-to-assess-postoperative-pneumonia-risk 2026-02-19T17:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/bioaffinity-technologies-reports-146-growth-in-cypath-lung-test-sales-as-clinical-case-studies-demonstrate-diagnostic-value 2026-02-19T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/northstrive-biosciences-advances-el-32-manufacturing-for-muscle-preservation-in-glp-1-therapy-patients 2026-02-19T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/dror-ortho-design-receives-fda-510-k-clearance-for-ai-powered-sleep-based-orthodontic-system 2026-02-19T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-garetosmab-for-ultra-rare-bone-disease-fibrodysplasia-ossificans-progressiva 2026-02-19T13:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/yoltech-s-yolt-202-gene-editing-therapy-shows-promising-results-in-alpha-1-antitrypsin-deficiency-trial 2026-02-19T13:02:12+00:00 hourly 0.9 https://trial.medpath.com/news/healwell-ai-and-well-health-launch-welltrust-platform-to-accelerate-clinical-trial-patient-recruitment 2026-02-19T13:01:16+00:00 hourly 0.9 https://trial.medpath.com/news/catheter-precision-divests-atherectomy-assets-for-15000-to-focus-on-electrophysiology-growth 2026-02-19T10:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-raises-850-million-in-debut-bond-offering-to-finance-amicus-therapeutics-acquisition 2026-02-19T09:02:03+00:00 hourly 0.9 https://trial.medpath.com/news/eupraxia-pharmaceuticals-raises-55-million-to-advance-eosinophilic-esophagitis-treatment 2026-02-19T05:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/organigram-completes-eur107-3-million-acquisition-of-sanity-group-with-british-american-tobacco-investment 2026-02-19T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sensei-biotherapeutics-acquires-faeth-therapeutics-for-200m-to-advance-pi3k-akt-mtor-pathway-inhibitor-piktor 2026-02-19T01:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-therapeutics-launches-pivya-first-novel-uti-antibiotic-in-decades-for-us-market 2026-02-19T01:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/avidity-s-del-desiran-shows-promise-for-myotonic-dystrophy-type-1-in-phase-1-2-marina-trial-published-in-nejm 2026-02-19T01:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/cyanocapture-and-persist-ai-partner-to-build-world-s-first-robotic-gmp-facility-for-oral-protein-and-peptide-drugs 2026-02-19T01:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/terumo-launches-revolutionary-blood-collection-tubes-using-snake-venom-derived-technology-in-japan 2026-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/monkeypox-treatment-pipeline-expands-with-mrna-vaccines-and-novel-therapeutics-from-major-pharma-companies 2026-02-18T21:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/zealand-pharma-reports-positive-phase-1a-results-for-novel-kv1-3-channel-blocker-zp9830-in-autoimmune-disease-development 2026-02-18T21:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/theriva-biologics-licenses-syn-020-to-rasayana-therapeutics-in-38m-deal-for-gut-targeted-therapy 2026-02-18T21:14:57+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-mrna-vaccine-shows-durable-immune-responses-in-triple-negative-breast-cancer-trial 2026-02-18T21:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/sift-biosciences-raises-3-7m-to-develop-memory-t-cell-immunotherapy-platform-for-cold-tumors 2026-02-18T21:11:33+00:00 hourly 0.9 https://trial.medpath.com/news/ankyra-therapeutics-unveils-first-in-class-cd137-anchored-immunotherapy-ank-203-with-promising-preclinical-anti-tumor-activity 2026-02-18T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/israeli-biotech-starget-pharma-raises-18m-to-advance-ai-driven-radiopharmaceutical-cancer-therapies 2026-02-18T21:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/tarsus-pharmaceuticals-appoints-former-allergan-ceo-david-pyott-to-board-of-directors 2026-02-18T21:11:03+00:00 hourly 0.9 https://trial.medpath.com/news/feinstein-institutes-scientists-transform-detrimental-immune-element-into-novel-sepsis-and-rheumatoid-arthritis-therapy 2026-02-18T21:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-completes-phase-0-trial-of-igf-antibody-xentuzumab-in-prostate-cancer-patients 2026-02-18T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/korsana-biosciences-emerges-with-175m-to-develop-next-generation-alzheimer-s-antibody-therapy 2026-02-18T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/newbiologix-publishes-breakthrough-hek293-cell-line-data-showing-two-fold-improvement-in-gene-therapy-vector-production 2026-02-18T17:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/rna-interference-therapy-market-expands-with-90-drugs-in-development-across-40-companies 2026-02-18T17:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/pluri-secures-china-patent-for-large-scale-immune-cell-manufacturing-platform 2026-02-18T17:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/grunenthal-initiates-phase-i-trial-of-novel-nav-1-8-inhibitor-for-non-opioid-pain-management 2026-02-18T17:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/oncohost-breakthrough-enables-integration-of-serum-and-plasma-proteomic-data-for-enhanced-cancer-biomarker-research 2026-02-18T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-secures-fda-approval-for-pediatric-pah-treatment-while-launching-respiratory-device-in-india 2026-02-18T17:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/unnatural-products-partners-with-novartis-in-1-7-billion-macrocyclic-peptide-deal-for-cardiovascular-therapeutics 2026-02-18T17:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-two-rapid-tests-for-critical-drug-resistant-pathogens 2026-02-18T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/acrivon-therapeutics-launches-clia-certified-laboratory-to-advance-precision-medicine-development 2026-02-18T17:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/rezon-bio-secures-fda-approval-for-commercial-biosimilar-manufacturing-at-warsaw-duchnice-facility 2026-02-18T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-national-cancer-clinical-trials-alliance-and-liquid-biopsy-foundation-to-address-growing-cancer-burden 2026-02-18T17:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/xingimaging-selected-to-lead-imaging-operations-for-landmark-alzheimer-s-tau-platform-phase-ii-trial 2026-02-18T17:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/trellus-health-secures-six-month-extension-with-johnson-johnson-for-ibd-digital-platform 2026-02-18T12:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacelera-secures-eur6m-to-accelerate-quantum-ai-drug-discovery-platform-in-us-market 2026-02-18T12:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-drug-discovery-startup-peptris-secures-7-7m-series-a-to-advance-clinical-pipeline 2026-02-18T12:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-achieve-14-million-fold-expansion-of-cancer-fighting-nk-cells-from-single-stem-cell 2026-02-18T05:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-s-pharmac-proposes-funding-for-two-chronic-lymphocytic-leukemia-combination-therapies 2026-02-18T01:04:19+00:00 hourly 0.9 https://trial.medpath.com/news/watchmaker-genomics-licenses-crispr-cas9-technology-from-caribou-biosciences-for-novel-ngs-library-normalization 2026-02-18T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/seek-labs-receives-2-million-usda-grant-to-develop-crispr-based-mutation-resistant-avian-flu-therapeutic 2026-02-18T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/klotho-neurosciences-secures-australian-patent-for-novel-gene-therapy-targeting-motor-neuron-diseases 2026-02-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mayo-clinic-becomes-first-u-s-institution-to-deploy-magnetic-nanoparticle-hyperthermia-technology-for-cancer-research 2026-02-17T21:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/calibr-skaggs-and-kainomyx-launch-gates-foundation-backed-collaboration-to-develop-novel-antimalarial-drugs-targeting-parasite-cytoskeleton 2026-02-17T21:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/rna-targeting-small-molecules-emerge-as-new-frontier-in-drug-discovery-with-major-pharma-partnerships 2026-02-17T21:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-researchers-develop-nanoparticle-based-gene-editing-platform-for-cystic-fibrosis-treatment 2026-02-17T21:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-industry-faces-growing-revenue-pressures-from-pricing-and-reimbursement-delays 2026-02-17T21:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/kansas-city-partners-launch-integrated-theranostics-platform-for-adult-and-pediatric-patients 2026-02-17T21:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/fred-hutch-scientists-develop-first-human-monoclonal-antibodies-to-block-epstein-barr-virus-infection 2026-02-17T21:02:17+00:00 hourly 0.9 https://trial.medpath.com/news/terns-pharmaceuticals-gains-institutional-interest-as-stock-surges-830-following-pipeline-updates 2026-02-17T17:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/largest-metabolomic-study-of-car-t-cell-therapy-reveals-new-biomarkers-for-predicting-severe-neurotoxicity 2026-02-17T17:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/omeros-reports-breakthrough-primate-study-results-for-novel-aml-therapeutic-oncotox-aml 2026-02-17T17:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/cyrano-therapeutics-reports-positive-phase-2-results-for-cyr-064-in-persistent-post-viral-smell-loss 2026-02-17T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/scinai-immunotherapeutics-completes-acquisition-of-recipharm-israel-and-forms-strategic-cdmo-partnership 2026-02-17T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/texas-community-cancer-center-launches-first-car-t-program-outside-hospital-setting 2026-02-17T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/andelyn-biosciences-partners-with-drake-rayden-foundation-to-manufacture-aav-gene-therapy-for-rare-nkh-disease 2026-02-17T17:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/essential-pharma-acquires-ventavis-for-primary-pulmonary-hypertension-from-bayer-ag 2026-02-17T17:03:40+00:00 hourly 0.9 https://trial.medpath.com/news/diakonos-oncology-s-doc1021-clears-first-safety-review-in-phase-2-glioblastoma-trial 2026-02-17T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/evogene-partners-with-queensland-university-to-develop-ai-driven-cancer-therapeutics-for-chemotherapy-resistant-lung-cancer 2026-02-17T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-appoints-brian-piper-as-cfo-ahead-of-key-clinical-data-readouts 2026-02-17T17:02:45+00:00 hourly 0.9 https://trial.medpath.com/news/retia-medical-receives-fda-clearance-for-argos-infinity-cardiovascular-intelligence-platform 2026-02-17T17:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/portal-diabetes-receives-fda-breakthrough-designation-for-implantable-insulin-pump-system 2026-02-17T17:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-tirabrutinib-nda-for-rare-brain-lymphoma-under-accelerated-approval-pathway 2026-02-17T17:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-bristol-myers-squibb-s-iberdomide-nda-for-multiple-myeloma-testing-new-regulatory-flexibility 2026-02-17T17:02:26+00:00 hourly 0.9 https://trial.medpath.com/news/nimbus-therapeutics-advances-novel-sik2-inhibitors-for-inflammatory-bowel-disease-with-dual-anti-inflammatory-and-mucosal-healing-mechanism 2026-02-17T17:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/instanosis-receives-fda-breakthrough-device-designation-for-rapid-xylazine-urine-test 2026-02-17T17:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/viiv-healthcare-advances-ultra-long-acting-hiv-pipeline-with-third-generation-integrase-inhibitor-vh184-data-at-croi-2026 2026-02-17T17:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-drug-amd3100-overcomes-immunotherapy-resistance-in-rare-liver-cancer 2026-02-17T17:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/salipro-biotech-secures-key-u-s-patent-for-membrane-protein-platform-extending-protection-until-2042 2026-02-17T13:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-and-teva-s-duvakitug-shows-sustained-efficacy-in-phase-2b-maintenance-study-for-inflammatory-bowel-disease 2026-02-17T13:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/circio-s-circvec-platform-achieves-50-fold-gene-expression-enhancement-in-eye-disease-applications 2026-02-17T13:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/roche-appoints-cancer-researcher-mark-dawson-to-lead-pharma-research-division 2026-02-17T13:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/nuclera-and-leadxpro-partner-to-accelerate-ai-driven-drug-discovery-for-challenging-membrane-proteins 2026-02-17T13:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/teijin-and-aska-pharmaceutical-partner-to-develop-ai-driven-gynecological-therapeutics 2026-02-17T13:02:38+00:00 hourly 0.9 https://trial.medpath.com/news/beactica-secures-eur2-5-million-eic-grant-to-advance-first-in-class-glioblastoma-therapy-bea-17-toward-clinical-trials 2026-02-17T13:02:11+00:00 hourly 0.9 https://trial.medpath.com/news/prognica-labs-and-nextgen-immuno-therapeutics-form-strategic-partnership-to-advance-ai-powered-precision-immunology 2026-02-17T13:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-considers-revoking-safety-status-of-processed-carbohydrates-as-health-industry-faces-major-regulatory-and-corporate-shifts 2026-02-17T09:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/danaher-acquires-masimo-for-9-9-billion-to-expand-patient-monitoring-portfolio 2026-02-17T09:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/oeb-6-emerges-as-new-manufacturing-standard-for-ultra-potent-oncology-drugs-and-adcs 2026-02-17T03:01:23+00:00 hourly 0.9 https://trial.medpath.com/news/edwards-lifesciences-withdraws-anti-copycat-policy-as-eu-closes-antitrust-investigation 2026-02-17T01:01:27+00:00 hourly 0.9 https://trial.medpath.com/news/uk-veterinary-regulator-confirms-safety-profile-of-canine-osteoarthritis-drug-librela-following-comprehensive-review 2026-02-16T21:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/single-dmt-dose-shows-rapid-lasting-antidepressant-effects-in-treatment-resistant-depression-trial 2026-02-16T21:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/tozaro-secures-ps6-million-to-reduce-gene-therapy-manufacturing-costs-with-smart-polymer-platform 2026-02-16T17:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/zemcelpro-receives-nub-status-1-in-germany-enabling-immediate-hospital-reimbursement-applications 2026-02-16T17:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-retevmo-shows-significant-event-free-survival-benefit-in-early-stage-ret-fusion-positive-lung-cancer 2026-02-16T17:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/artios-pharma-strengthens-leadership-team-with-three-key-appointments-to-advance-dna-damage-response-pipeline 2026-02-16T17:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/lex-diagnostics-receives-fda-510-k-clearance-for-ultra-fast-point-of-care-pcr-system 2026-02-16T17:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-foxg1-gene-therapy-for-clinical-trials-in-rare-neurodevelopmental-disorder 2026-02-16T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-researchers-report-first-case-of-type-2-diabetes-reversal-using-stem-cell-therapy 2026-02-16T13:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/seismic-consortium-secures-eur23-5-million-to-develop-next-generation-minimally-invasive-brain-surgery-technologies 2026-02-16T13:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/bio-techne-s-ella-platform-receives-ce-ivd-marking-expanding-rapid-immunoassay-access-in-european-clinical-laboratories 2026-02-16T13:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/harness-therapeutics-advances-first-in-class-huntington-s-disease-drug-hrn001-toward-clinical-trials 2026-02-16T13:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-s-e2086-receives-orphan-drug-designation-in-japan-for-narcolepsy-treatment 2026-02-16T13:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/immunic-raises-400m-to-advance-first-in-class-multiple-sclerosis-therapy-toward-commercial-launch 2026-02-16T13:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/quidelortho-partners-with-lifotronic-technology-to-expand-global-immunoassay-portfolio 2026-02-16T09:01:43+00:00 hourly 0.9 https://trial.medpath.com/news/cstone-s-novel-trispecific-antibody-cs2009-receives-fda-clearance-for-phase-ii-trial-in-advanced-solid-tumors 2026-02-16T05:01:18+00:00 hourly 0.9 https://trial.medpath.com/news/neogenomics-launches-pantracer-pro-to-streamline-advanced-solid-tumor-testing 2026-02-15T21:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/uae-partners-with-insilico-medicine-to-launch-ai-driven-drug-discovery-initiative 2026-02-15T21:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/phathom-pharmaceuticals-refocuses-on-gastroenterology-projects-profitability-by-second-half-2026 2026-02-15T12:32:44+00:00 hourly 0.9 https://trial.medpath.com/news/iran-advances-to-7th-place-globally-in-regenerative-medicine-with-six-new-atmp-approvals 2026-02-15T12:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/oncores-medical-raises-a-27-million-to-advance-real-time-breast-cancer-surgery-imaging-technology 2026-02-15T01:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-launches-world-s-largest-mental-health-study-to-develop-personalized-treatments-for-severe-mental-illness 2026-02-15T01:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/alkem-laboratories-enters-cardiovascular-device-market-with-eur99-4-million-occlutech-acquisition 2026-02-14T21:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/nxera-pharma-licenses-gpcr-targeted-program-to-investment-firm-backed-spin-out-company 2026-02-14T21:01:31+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-secures-fda-approval-for-generic-ammonium-lactate-cream-for-dry-skin-conditions 2026-02-14T17:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-confirms-single-pivotal-study-standard-for-drug-approval-accelerating-cinclus-pharma-s-gerd-treatment-path 2026-02-14T04:40:43+00:00 hourly 0.9 https://trial.medpath.com/news/galecto-raises-316-3-million-in-public-offering-to-advance-blood-cancer-therapeutics-pipeline 2026-02-14T04:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-pivots-to-international-markets-after-fda-rejects-flu-vaccine-application 2026-02-14T04:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/deuterium-depletion-shows-promise-as-novel-cancer-therapy-through-gene-expression-modulation 2026-02-14T04:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/nk-cell-engager-development-faces-mounting-setbacks-as-beone-medicines-and-novartis-discontinue-programs 2026-02-14T04:35:01+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-therapies-enable-long-term-survival-in-multiple-myeloma-patients-through-second-stem-cell-transplants 2026-02-13T21:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/bracco-and-acist-medical-systems-launch-next-generation-acist-pro-diagnostic-system-in-europe 2026-02-13T21:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-advances-multi-target-ibd-strategy-with-combination-therapies-and-subcutaneous-skyrizi-data-expected 2026-02-13T21:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/icmr-study-confirms-six-month-oral-tb-regimens-reduce-costs-while-improving-outcomes-for-drug-resistant-cases 2026-02-13T21:02:46+00:00 hourly 0.9 https://trial.medpath.com/news/hcw-biologics-and-wy-biotech-launch-joint-venture-trimmune-to-advance-cancer-immunotherapy-hcw11-006 2026-02-13T17:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-withdrawal-of-levamisole-medicines-from-eu-market-due-to-serious-brain-side-effects 2026-02-13T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/china-medical-system-partners-with-insilico-medicine-for-ai-drug-discovery-advances-complement-inhibitor-to-clinical-trials 2026-02-13T17:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-s-acrotech-receives-fda-approval-for-adquey-first-non-steroidal-pde4-inhibitor-for-atopic-dermatitis 2026-02-13T17:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/nasus-pharma-raises-15-million-to-advance-needle-free-epinephrine-treatment-for-anaphylaxis 2026-02-13T17:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/precision-biologics-presents-preclinical-data-on-novel-pb-223-adc-targeting-truncated-core-2-glycans-in-solid-tumors 2026-02-13T17:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-biomed-launches-120-patient-study-to-validate-3d-cell-culture-platform-for-precision-cancer-treatment 2026-02-13T17:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-breztri-shows-significant-lung-function-improvements-in-phase-iii-asthma-trials 2026-02-13T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/iterum-therapeutics-expands-orlynvah-market-access-while-fda-requires-additional-clinical-trial-for-step-down-therapy 2026-02-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-integration-and-ps45-million-investment-signal-new-era-for-alzheimer-s-drug-discovery 2026-02-13T12:38:50+00:00 hourly 0.9 https://trial.medpath.com/news/national-cancer-institute-launches-multi-cancer-blood-test-trial-at-eight-centers-nationwide 2026-02-13T08:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/genfit-receives-20m-milestone-as-iqirvo-exceeds-200m-sales-threshold-in-first-year 2026-02-13T04:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/japan-grants-world-first-pharmaceutical-approval-for-human-milk-based-fortifier-in-neonatal-care 2026-02-13T04:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-initiates-phase-3-trial-of-ibi354-her2-adc-for-first-line-her2-positive-breast-cancer-treatment 2026-02-13T04:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-s-bocunebart-meets-primary-endpoint-in-phase-iib-migraine-prevention-trial 2026-02-13T04:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/neuroendocrine-tumor-pipeline-shows-promise-with-75-therapies-in-development-and-recent-fda-approvals 2026-02-13T04:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/ptc-therapeutics-withdraws-translarna-nda-for-duchenne-muscular-dystrophy-following-fda-feedback 2026-02-13T04:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-recommend-approval-of-first-whim-syndrome-treatment 2026-02-13T04:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-partners-with-median-technologies-to-integrate-fda-cleared-ai-lung-cancer-screening-tool 2026-02-13T04:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/inventiva-s-lanifibranor-achieves-dual-endpoints-in-nash-trial-analysts-project-2-6b-peak-sales 2026-02-13T01:01:24+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-challenges-medicare-price-controls-on-botox-citing-plasma-derived-product-exemption 2026-02-12T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/major-study-finds-no-link-between-covid-19-mrna-vaccination-during-pregnancy-and-neurodevelopmental-disorders-in-children 2026-02-12T21:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/centivax-begins-phase-1-trial-of-universal-flu-vaccine-targeting-all-strains 2026-02-12T21:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/arvinas-appoints-randy-teel-as-ceo-following-first-successful-protac-pivotal-trial 2026-02-12T17:20:25+00:00 hourly 0.9 https://trial.medpath.com/news/biolife-solutions-expands-into-500-million-cytokines-market-through-exclusive-qkine-partnership 2026-02-12T17:19:56+00:00 hourly 0.9 https://trial.medpath.com/news/aardvark-therapeutics-establishes-dermatology-subsidiary-ardia-to-advance-novel-psoriasis-treatment-dia-615 2026-02-12T17:16:43+00:00 hourly 0.9 https://trial.medpath.com/news/zeon-corporation-invests-in-digital-chemistry-pioneer-chemify-to-accelerate-automated-drug-discovery 2026-02-12T17:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/oncotelic-therapeutics-expands-global-patent-protection-for-ot-101-tgf-b-antisense-therapy-across-cns-and-neurology-applications 2026-02-12T17:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/discus-trial-results-prompt-nhs-to-reduce-chemotherapy-cycles-for-advanced-bladder-cancer 2026-02-12T17:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/caredx-s-ai-powered-alloheme-test-detects-aml-and-mds-relapse-41-days-earlier-than-standard-methods 2026-02-12T17:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/apertura-gene-therapy-launches-open-aperture-program-to-democratize-access-to-cns-targeting-aav-capsid 2026-02-12T17:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/nanoviricides-files-orphan-drug-application-for-nv-387-mpox-treatment-amid-current-therapy-failures 2026-02-12T17:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/totus-medicines-to-present-updated-phase-1-data-for-novel-covalent-pi3ka-inhibitor-tos-358-at-esmo-tat-congress 2026-02-12T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/grace-therapeutics-awaits-fda-decision-on-gtx-104-for-aneurysmal-subarachnoid-hemorrhage-with-april-2026-pdufa-date 2026-02-12T17:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-s-oral-infigratinib-achieves-breakthrough-results-in-phase-3-achondroplasia-trial 2026-02-12T17:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/encora-therapeutics-receives-fda-510-k-clearance-for-wearable-essential-tremor-device 2026-02-12T17:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-s-oral-dwarfism-drug-infigratinib-achieves-best-in-class-results-in-pivotal-achondroplasia-trial 2026-02-12T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/neupulse-secures-ps3-million-to-advance-tourette-syndrome-wearable-device-toward-2026-launch 2026-02-12T13:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/biological-e-receives-who-phase-ii-pre-qualification-for-novel-oral-polio-vaccine-type-2 2026-02-12T13:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-99mtc-maraciclatide-for-interstitial-lung-disease-imaging 2026-02-12T13:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/valar-labs-publishes-ai-breakthrough-for-pancreatic-cancer-treatment-selection-in-journal-of-clinical-oncology 2026-02-12T09:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/arkbio-receives-fda-clearance-for-phase-2-trial-of-novel-anti-fibrotic-drug-ak3280-in-idiopathic-pulmonary-fibrosis 2026-02-12T09:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-genetic-mechanism-behind-rare-blood-clotting-in-johnson-johnson-and-astrazeneca-covid-vaccines 2026-02-12T05:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-novocure-s-optune-pax-for-locally-advanced-pancreatic-cancer-first-new-treatment-in-nearly-30-years 2026-02-12T05:02:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warnings-over-sexual-enhancement-products-containing-undeclared-prescription-drug-ingredients 2026-02-12T05:01:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-optune-pax-for-locally-advanced-pancreatic-cancer-first-new-treatment-in-nearly-30-years 2026-02-12T05:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/pharmap-2026-to-showcase-patient-centric-medicine-and-regulatory-harmonization-in-amsterdam 2026-02-12T02:30:41+00:00 hourly 0.9 https://trial.medpath.com/news/speed-based-brain-training-reduces-dementia-risk-by-25-in-20-year-clinical-trial 2026-02-12T01:04:52+00:00 hourly 0.9